US5691317A - Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer - Google Patents
Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer Download PDFInfo
- Publication number
- US5691317A US5691317A US08/383,742 US38374295A US5691317A US 5691317 A US5691317 A US 5691317A US 38374295 A US38374295 A US 38374295A US 5691317 A US5691317 A US 5691317A
- Authority
- US
- United States
- Prior art keywords
- sub
- antisense
- cells
- rii
- camp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract description 43
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract description 43
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract description 23
- 230000001105 regulatory effect Effects 0.000 title abstract description 10
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 title abstract description 7
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 title description 48
- 201000011510 cancer Diseases 0.000 title description 23
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000000295 complement effect Effects 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 125000002328 sterol group Chemical group 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000005907 cancer growth Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 description 126
- 210000004027 cell Anatomy 0.000 description 101
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 65
- 230000000694 effects Effects 0.000 description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 230000009036 growth inhibition Effects 0.000 description 15
- 230000012010 growth Effects 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010029260 Neuroblastoma Diseases 0.000 description 6
- 108091006374 cAMP receptor proteins Proteins 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- GDDBIAMRTVTOBL-LSCFUAHRSA-N (4ar,6r,7r,7as)-6-[6-(benzylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound N1=CN=C2N([C@H]3[C@@H]([C@@H]4OP(O)(=O)OC[C@H]4O3)O)C=NC2=C1NCC1=CC=CC=C1 GDDBIAMRTVTOBL-LSCFUAHRSA-N 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000005222 photoaffinity labeling Methods 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 description 4
- WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000009422 growth inhibiting effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 108010082683 kemptide Proteins 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000010749 gastric carcinoma Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 208000025036 lymphosarcoma Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- -1 nucleoside phosphorothioates Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003909 protein kinase inhibitor Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 2
- 108700020473 Cyclic AMP Receptor Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000009971 Walker Carcinoma 256 Diseases 0.000 description 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 101710176215 cAMP-dependent protein kinase type I regulatory subunit Proteins 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Definitions
- the invention is in the field of medicinal chemistry.
- the invention relates to certain antisense oligonucleotides and the use thereof for the treatment of cancer.
- cAMP an intracellular regulatory agent, has been considered to have a role in the control of cell proliferation and differentiation (Pastan, I., Johnson, G. S. & Anderson, W. B. (1975) Ann. Rev. Biochem. 44, 491-522; Prasad, K. N. (1975) Biol. Rev. 50, 129-165; Cho-Chung, Y. S. (1980) J.
- the type I and type II protein kinases are distinguished by their regulatory subunits (RI and RII, respectively) (Corbin, J. D., Keely, S. L. & Park, C. R. (1975) J. Biol. Chem. 250, 218-225; Hofmann, F., Beavo, J. A. & Krebs, E. G. (1975) J. Biol. Chem. 250, 7795-7801).
- RI.sub. ⁇ Four different regulatory subunits RI.sub. ⁇ (previously designated RI) (Lee, D. C., Carmichael, D. F., Krebs, E. G. & McKnight, G. S. (1983) Proc. Natl. Acad. Sci. USA 80, 3608-3612) , RI.sub. ⁇ (Clegg, C. H., Cadd, G. G. & McKnight, G. S. (1988) Proc. Natl. Acad. Sci. USA 85, 3703-3707), RII.sub. ⁇ (RII 54 ) (Scott, J. D., Glaccum, M. B., Zoller, M. J., Uhler, M.
- the growth inhibition further correlates with a rapid translocation of RII.sub. ⁇ to the nucleus and an increase in the transcription of the RII.sub. ⁇ gene (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., .O slashed.greid, D., D.o slashed.skeland, S. O., Jahnsen, T. & Cho-Chung, Y. S. (1988) Proc, Natl. Acad, Sci. USA 85, 6319-6322).
- RII.sub. ⁇ plays an important role in the cAMP growth regulatory function (Cho-Chung, Y. S. (1989) J. Natl. Cancer Inst. 81, 982-987).
- Antisense RNA sequences have been described as naturally occurring biological inhibitors of gene expression in both prokaryotes (Mizuno, T., Chou, M-Y, and Inouye, M. (1984), Proc. Natl. Acad. Sci. USA 81, (1966-1970)) and eukaryotes (Heywood, S. M. Nucleic Acids Res., 14, 6771-6772 (1986)), and these sequences presumably function by hybridizing to complementary mRNA sequences, resulting in hybridization arrest of translation (Paterson, B. M., Roberts, B. E., and Kuff, E. L., (1977) Proc. Natl. Acad. Sci. USA, 74, 4370-4374.
- Antisense oligodeoxynucleotides are short synthetic nucleotide sequences formulated to be complementary to a specific gene or RNA message. Through the binding of these oligomers to a target DNA or mRNA sequence, transcription or translation of the gene can be selectively blocked and the disease process generated by that gene can be halted.
- the cytoplasmic location of mRNA provides a target considered to be readily accessible to antisense oligodeoxynucleotides entering the cell; hence much of the work in the field has focused on RNA as a target.
- the invention is related to the discovery that inhibiting the expression of RI.sub. ⁇ in leukemia cells by contact with an antisense O-oligonucleotides and S-oligonucleotides for RI.sub. ⁇ results in the inhibition of proliferation and the stimulation of cell differentiation. Accordingly, the invention is directed to RI.sub. ⁇ antisense oligonucleotides and pharmaceutical compositions thereof for the treatment of cancer.
- the invention is related to 15- to 30-mer antisense oligonucleotides which are complementary to a region in the first 100 N-terminal codons of RI.sub. ⁇ (Seq. ID No:6).
- the invention is also related to 15- to 30-mer antisense oligonucleotides which are a fragment of antisense DNA complementary to RI.sub. ⁇ (Seq. ID No: 5).
- the invention is also related to pharmaceutical compositions comprising at least one 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI.sub. ⁇ (Seq. ID No:6); and a pharmaceutically acceptable carrier.
- the invention is also related to a method for treating cancer by suppressing growth of cancer cells susceptible to growth suppression and for inducing cancer cell differentiation in an animal comprising administering to an animal in need of such treatment a cancer cell growth suppressing amount of an RI.sub. ⁇ antisense oligonucleotide.
- FIGS. 1A and 1B depict a graph showing the effect of RI.sub. ⁇ antisense oligodeoxynucleotide (SEQ ID NO:1) on the basal rate of growth of HL-60 leukemic cells (A) and the growth of these cells when treated with cAMP -analogs or TPA (B).
- A cells were grown (see the Examples) in the absence ( ⁇ ) or presence ( ⁇ ) of RI.sub. ⁇ antisense oligodeoxynucleotide (15 ⁇ M). At indicated times, cell counts in duplicate were performed. Data represent the average values ⁇ SD of four experiments.
- the data represent the average values ⁇ SD of four experiments.
- FIGS. 2A, 2B, 2C, 2D, 2E and 2F depict the effect of RI.sub. ⁇ antisense oligodeoxynucleotide (SEQ ID NO:1) on the morphologic transformation of HL-60 cells.
- Cells either exposed or unexposed to RI.sub. ⁇ antisense oligodeoxynucleotide were treated with cAMP analogs or TPA as described in FIG. 1B.
- cAMP analogs or TPA as described in FIG. 1B.
- day 4 see FIG. 1B
- cells were washed twice in Dulbecco's phosphate-buffered saline and were pelleted onto a glass slide by cytocentrifuge. The resulting cytopreparations were fixed and stained by Wright's stain. ⁇ 180.
- FIGS. 3A and 3B depict a Northern blot showing decreased RI.sub. ⁇ mRNA expression in HL-60 leukemic cells exposed to RI.sub. ⁇ antisense oligodeoxynucleotide (SEQ ID NO:1). Cells were either exposed or unexposed to RI.sub. ⁇ antisense oligodeoxynucleotide (15 ⁇ M) for 8 hr. Isolation of total RNA and Northern blot analysis followed the methods described in the Examples. A, ethidium bromide staining of RNA; M, markers of ribosomal RNAs; lanes 1, 2, cells unexposed or exposed to RI.sub. ⁇ antisense oligomer. B, Northern blot analysis; the same nitrocellulose filter was hybridized to both RI.sub. ⁇ and actin probes in sequential manner. Lanes 1, 2, cells unexposed or exposed to RI.sub. ⁇ antisense oligomer.
- FIGS. 4A and 4B, and 4C depict an SDS-PAGE showing the effect of RI.sub. ⁇ antisense oligodeoxynucleotide on the basal and induced levels of RI.sub. ⁇ and RII.sub. ⁇ cAMP receptor proteins in HL-60 leukemic cells.
- Cells were either exposed to RI.sub. ⁇ antisense oligodeoxynucleotide (SEQ ID NO:1) (15 ⁇ M) or treated with cAMP analogs as described in FIG. 1.
- SEQ ID NO:1 RI.sub. ⁇ antisense oligodeoxynucleotide
- cAMP and immunoprecipitation using the anti-RI.sub. ⁇ or anti-RII.sub. ⁇ antiserum and protein A Sepharose, and SDS-PAGE of solubilized antigen-antibody complex followed the methods described in the Examples.
- Pre-immune serum controls were carried out simultaneously and detected no immunoprecipitated band.
- M 14 C-labeled marker proteins of known molecular weight; RI.sub. ⁇ , the 48,000 molecular weight RI (Sigma); RII.sub. ⁇ , the 56,000 molecular weight RII (Sigma).
- Lanes RI.sub. ⁇ and RII.sub. ⁇ are from photoaffinity labeling with 8-N 3 - 32 P!cAMP only; lanes 1 to 3, photoaffinity labeling with 8-N 3 - 32 P!cAMP followed by immunoprecipitation with anti-RI.sub. ⁇ or anti-RII.sub. ⁇ antiserum.
- 8-Cl, 8-Cl-cAMP (5 ⁇ M); N 6 -benzyl,N 6 -benzyl-cAMP (5 ⁇ M).
- the data in the table represent quantification by densitometric scanning of the autoradiograms.
- the data are expressed relative to the levels in control cells unexposed to RI.sub. ⁇ antisense oligomer and untreated with cAMP analog, which are set equal to 1 arbitrary unit.
- the data represent an average ⁇ SD of three experiments. A and B, immunoprecipitation with anti-RI.sub. ⁇ and anti-RII.sub. ⁇ antisera, respectively.
- FIGS. 5A, 5B, 5C and 5D depict graphs showing the growth inhibition of human cancer cell lines by RI.sub. ⁇ antisense oligodeoxynucleotide having SEQ ID No: 1 (O-oligo and S-oligo derivatives), compared to controls.
- E 2 estradiol-17 ⁇ .
- FIGS. 6A, 6B, and 6C depict the change in morphology of SK-N-SH human neuroblastoma cells exposed to RI.sub. ⁇ antisense oligodeoxynucleotide having SEQ ID No: 1.
- FIGS. 7A and 7B depict a graph showing that RI.sub. ⁇ antisense oligodeoxynucleotide and its phosphorothioate analog (SEQ ID NO:1) inhibit the in vivo growth of LS-174T human colon carcinoma in athymic mice.
- FIG. 7A shows the oligodeoxynucleotide concentration-dependent inhibition of tumor growth.
- O-oligo RI.sub. ⁇ antisense oligodeoxynucleotide
- S-oligo phosphorothioate analog of RI.sub. ⁇ antisense oligomer.
- the cholesterol pellets total weight 20 mg
- containing the indicated doses of O-oligo or S-oligo were implanted s.c.
- FIG. 7B shows the temporal effect of antisense oligodeoxynucleotide phosphorothioate analogs on tumor growth. S-oligos as indicated at 0.3 mg dose in cholesterol pellets (total weight 20 mg) were implanted s.c. 2 ⁇ /week, and tumor volume (see Materials and Methods, Example 3) represents an average ⁇ S.D. of 7 tumors.
- Antisense therapy is the administration of exogenous oligonucleotides which bind to a target polynucleotide located within the cells.
- the term "antisense” refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., RI.sub. ⁇ . See for example, Jack Cohen, OLIGODEOXYNUCLEOTIDES, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988).
- the RI.sub. ⁇ antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, supra) which exhibit enhanced cancer cell growth inhibitory action (see FIGS. 5 and 7A).
- S-oligos are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom.
- the S-oligos of the present invention may be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide which is a sulfur transfer reagent. See Iyer, R. P. et al, J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. et al., J. Am. Chem. Soc. 112:1253-1254 (1990), the disclosures of which are fully incorporated by reference herein.
- the RI.sub. ⁇ antisense oligonucleotides of the present invention may be RNA or DNA which is complementary to and stably hybridizes with the first 100 N-terminal codons of the RI.sub. ⁇ genome or the corresponding mRNA.
- Use of an oligonucleotide complementary to this region allows for the selective hybridization to RI.sub. ⁇ mRNA and not to mRNA specifying other regulatory subunits of protein kinase.
- the RI.sub. ⁇ antisense oligonucleotides of the present invention are a 15 to 30-mer fragment of the antisense DNA molecule having SEQ ID NO:5 which hybridizes to RI.sub. ⁇ mRNA.
- RI.sub. ⁇ antisense oligonucleotide is a 15- to 30-mer oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI.sub. ⁇ (Seq. ID No:6).
- the RI.sub. ⁇ antisense oligonucleotide has SEQ ID No:1, SEQ ID No:2, SEQ ID No:3, or SEQ ID No:4.
- compositions comprising an effective amount of at least one of the RI.sub. ⁇ antisense oligonucleotides of the invention in combination with a pharmaceutically acceptable carrier.
- a single RI.sub. ⁇ antisense oligonucleotide is utilized.
- two RI.sub. ⁇ antisense oligonucleotides are utilized which are complementary to adjacent regions of the RI.sub. ⁇ genome.
- RI.sub. ⁇ antisense oligonucleotides which are complementary to adjacent regions of the RI.sub. ⁇ genome or corresponding mRNA may allow for more efficient inhibition of RI.sub. ⁇ genomic transcription or mRNA translation, resulting in more effective inhibition of cancer cell growth.
- the RI.sub. ⁇ antisense oligonuoleotide is coadministered with an agent which enhances the uptake of the antisense molecule by the cells.
- the RI.sub. ⁇ antisense oligonucleotide may be combined with a lipophilic cationic compound which may be in the form of liposomes.
- liposomes to introduce nucleotides into cells is taught, for example, in U.S. Pat. Nos. 4,897,355 and 4,394,448, the disclosures of which are incorporated by reference in their entirety. See also U.S. Pat. Nos. 4,235,871, 4,231,877, 4,224,179, 4,753,788, 4,673,567, 4,247,411, 4,814,270 for general methods of preparing liposomes comprising biological materials.
- the RI.sub. ⁇ antisense oligonucleotide may be combined with a lipophilic carrier such as any one of a number of sterols including cholesterol, cholate and deoxycholic acid.
- a lipophilic carrier such as any one of a number of sterols including cholesterol, cholate and deoxycholic acid.
- a preferred sterol is cholesterol.
- the RI.sub. ⁇ antisense oligonucleotide may be conjugated to a peptide that is ingested by cells.
- useful peptides include peptide hormones, antigens or antibodies, and peptide toxins. By choosing a peptide that is selectively taken up by the neoplastic cells, specific delivery of the antisense agent may be effected.
- the RI.sub. ⁇ antisense oligonucleotide may be covalently bound via the 5'OH group by formation of an activated aminoalkyl derivative.
- the peptide of choice may then be covalently attached to the activated RI.sub. ⁇ antisense oligonucleotide via an amino and sulfhydryl reactive hereto bifunctional reagent.
- the latter is bound to a cysteine residue present in the peptide.
- the peptidyl antisense agent Upon exposure of cells to the RI.sub. ⁇ antisense oligonucleotide bound to the peptide, the peptidyl antisense agent is endocytosed and the RI.sub. ⁇ antisense oligonucleotide binds to the target RI.sub. ⁇ mRNA to inhibit translation. See PCT Application Publication No. PCT/US89/02363.
- the RI.sub. ⁇ antisense oligonucleotides of the present invention are useful in treating a variety of cancers, including, but not limited to, gastric, pancreatic, lung, breast, anal, colorectal, head and neck neoplasms, neuroblastomas, melanoma and various leukemias.
- the RI.sub. ⁇ antisense oligonucleotides of the invention may also be active against the following tumor systems: F9 teratocarcinoma, SK-N-SH neuroblastoma, TMK-1 gastric carcinoma, HL-60 promyelocytic Leukemia, Leukemia L-1210, Leukemia P388, P1534 leukemia, Friend Virus Leukemia, Leukemia L4946, Mecca lymphosarcoma, Gardner lymphosarcoma, Ridgway Osteogenic sarcoma, Sarcoma 180 (ascites), Wagner osteogenic sarcoma, Sarcoma T241, Lewis lung carcinoma, Carcinoma 755, CD8F, MCF-7 breast carcinoma, Colon 38, LS-174T colon carcinoma, Carcinoma 1025, Ehrlich carcinoma (ascites & solid), Krubs 2 carcinoma (ascites), Bashford carcinoma 63, Adenocarcinoma E 0771, B16 Melanoma, Hardin
- RI.sub. ⁇ antisense oligonucleotides and the pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose.
- administration may be by parenteral, subcutaneous, intravenous, intramuscular, intra-peritoneal, or transdermal routes.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- compositions within the scope of this invention include all compositions wherein the RI.sub. ⁇ antisense oligonucleotide is contained in an amount which is effective to achieve inhibition of proliferation and/or stimulate differentiation of the subject cancer cells. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill in the art.
- the RI.sub. ⁇ antisense oligonucleotide may be administered to mammals, e.g. humans, at a dose of 0.005 to 1 mg/kg/day, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated.
- the RI.sub. ⁇ antisense oligonucleotides may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the RI.sub. ⁇ antisense oligonucleotide into preparations which can be used pharmaceutically.
- Suitable formulations for parenteral administration include aqueous solutions of the RI.sub. ⁇ antisense oligonucleotides in water-soluble form, for example, water-soluble salts.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl cleats or triglycerides.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- the antisense oligonucleotides of the present invention may be prepared according to any of the methods that are well known to those of ordinary skill in the art.
- the antisense oligonucleotides are prepared by solid phase synthesis. See, Goodchild, J., Bioconjugate Chemistry, 1:165-167 (1990), for a review of the chemical synthesis of oligonucleotides.
- the antisense oligonucleotides can be obtained from a number of companies which specialize in the custom synthesis of oligonucleotides.
- the 21-mer oligodeoxynucleotides used in the present studies were synthesized at Midland Certified Reagent Co. (Midland, Tex.) and had the following sequences: human RI.sub. ⁇ (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) Biochem. Biophys. Res. Commun. 149, 939-945) antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3' (SEQ ID No:1); human RII.sub. ⁇ (Levy, F.
- antisense 5'-CGG-GAT-CTG-GAT-GTG-GCT-CAT-3'; and the random sequence oligodeoxynucleotide was made of a mixture of all four nucleotides at every position.
- cAMP analogs (kindly provided by Dr. R. K. Robins, Nucleic Acid Research Institute, Costa Mesa, Calif.) or 12-O-tetradecanoylphorbol-13-acetate (TPA) were added one time at day 0. Cell counts were performed on day 4.
- Cell extracts were prepared at 0°-4° C.
- the cell pellets (2 ⁇ 10 6 cells), after two washes with PBS, were suspended in 0.5 ml buffer Ten (0.1M NaCl, 5 mM MgCl 2 , 1% Nonidet P-40, 0.5% Na deoxycholate, 2 KIU/ml bovine aprotinin, and 20 mM Tris-HCl, pH 7.4) containing proteolysis inhibitors (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci.
- cell pellets (2 ⁇ 10 6 cells) were lysed in 0.5 ml of 20 mM Tris (pH 7.5), 0.1 mM sodium EDTA, 1 mM dithiothreitol, 0.1 mM pepstatin, 0.1 mM antipain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.4 mg/ml aprotinin, and 0.5 mg/ml soybean trypsin inhibitor, using 100 strokes of a Dounce homogenizer.
- RNA containing 20 mM 3- N-morpholine!propane-sulfonic acid (pH 7.0), 50% formamide, and 6% formaldehyde was denatured at 65° C. for 10 min and electrophoresed through a denaturing 1.2% agarose-2.2M formaldehyde gel. The gels were then transferred to Biotrans nylon membranes (ICN Biomedicals) by the method of Thomas (Thomas, P. S. (1980) Proc. Natl. Acad. Sci.
- the RI.sub. ⁇ antisense oligodeoxynucleotide at 15 ⁇ M concentration had immediate effects on the rate of proliferation of HL-60 cells.
- By 4-5 days in culture while cells unexposed to RI.sub. ⁇ antisense oligomer demonstrated an exponential rate of growth, cells exposed to the antisense oligomer exhibited a reduced growth rate and eventually stopped replicating (FIG. 1A).
- This inhibitory effect on cell proliferation persisted throughout the culture period.
- the growth inhibition was not due to cell killing; cells were over 90% viable after exposure to RI.sub. ⁇ antisense oligomer (15 ⁇ M) for 7 days as assessed by flow cytometry using forward and side scatter.
- RI.sub. ⁇ sense, RII.sub. ⁇ , or RII.sub. ⁇ antisense, or a random sequence oligodeoxynucleotide had no such growth inhibitory effect.
- HL-60 cells undergo a monocytic differentiation upon treatment withsite-selective cAMP analogs.
- Cells either unexposed or exposed to RI.sub. ⁇ antisense oligodeoxynucleotide were examined for their morphology before and after treatment with cAMP analogs.
- 8-Cl-cAMP plus N 6 -benzyl-cAMP induced a monocytic morphologic change characterized by a decrease in nuclear-to-cytoplasm ratio, abundant ruffled and vacuolated cytoplasm, and loss of nucleoli.
- the RI.sub. ⁇ mRNA level was determined. As shown in FIG. 3, 3.0 kb RI.sub. ⁇ mRNA (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) Biochem. Biophys. Res. Commun. 149, 939-945) was virtually undetectable in cells exposed for 8 hr to RI.sub. ⁇ antisense oligodeoxynucleotide (FIG.
- cAMP receptor proteins The levels of cAMP receptor proteins in these cells was then determined by immunoprecipitation using anti-RI.sub. ⁇ and anti-RII.sub. ⁇ antisera (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708; Ekanger, R., Sand, T. E., Ogreid, D., Christoffersen, T. & D.o slashed.skeland, S. O. (1985) J. Biol. Chem. 260, 3393-3401) after photoaffinity labeling of these receptor proteins with 8-N 3 - 32 P!cAMP.
- anti-RI.sub. ⁇ and anti-RII.sub. ⁇ antisera Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708;
- the increase in RII.sub. ⁇ may be responsible for the differentiation induced in these cells after exposure to RI.sub. ⁇ antisense oligodeoxynucleotide.
- the increase in RII.sub. ⁇ mRNA or RII.sub. ⁇ protein level has been correlated with cAMP analog-induced differentiation in K-562 chronic myelocytic leukemic cells (Tortora, G., Clair, T., Katsaros, D., Ally, S., Colamonici, O., Neckers, L. M., Tagliaferri, P., Jahnsen, T., Robins, R. K. & Cho-Chung, Y. S. (1989) Proc. Natl. Acad.
- RI.sub. ⁇ antisense oligodeoxynucleotide SEQ ID NO:1
- SEQ ID NO:1 RI.sub. ⁇ antisense oligodeoxynucleotide (SEQ ID NO:1)induced a marked increase in the expression of monocytic surface antigens Leu 15 (Landay, A., Gartland, L. & Clement, L. T. (1983) J. Immunol. 131, 2757-2761) and Leu M3 (Dimitriu-Bona, A., Burmester, G. R., Waters, S. J.
- RII.sub. ⁇ cAMP receptor was not detected in HL-60 cells (Cho-Chung, Y. S., Clair, T., Tagliaferri, P., Ally, S., Katsaros, D., Tortora, G., Neckers, L., Avery, T. L., Crabtree, G. W. & Robins, R. K. (1989) Cancer Invest. 7(2), 161-177), and RII.sub. ⁇ antisense oligodeoxynucleotide showed no interference with the effects of RI.sub. ⁇ antisense oligomer (Table 1).
- cAMP transduces signals for dual controls, either positive or negative, on cell proliferation, depending on the availability of RI.sub. ⁇ or RII.sub. ⁇ receptor proteins.
- the RI.sub. ⁇ antisense oligodeoxynucleotide which brought about suppression of RI.sub. ⁇ along with enhancement of RII.sub. ⁇ expression led to terminal differentiation of HL-60 leukemia with no sign of toxicity.
- Biol. Chem. 252, 4888-4894 as a substrate in the presence and absence of a saturating concentration of cAMP and in the presence and absence of the heat-stable protein kinase inhibitor (Cheng, H.-C., Van Patten, S. M., Smith, A. J. & Walsh, D. A. (1985) Biochem. J. 231, 655-661).
- This method of assay gives accurate determination of the relative levels of dissociated C and total C activity.
- Cell extracts from untreated HL-60 cells exhibited a very low level of dissociated C and were stimulated 36-fold by cAMP (Table 2).
- RI.sub. ⁇ cAMP receptor protein Over expression of RI.sub. ⁇ cAMP receptor protein has also been found in the majority of human breast and colon primary carcinomas examined (Bradbury, A. W., Miller, W. R., Clair, T., Yokozaki, H. & Cho-Chung, Y. S. (1990) Proc. Am. Assoc. Cancer Res. 31, 172), suggesting an important in vivo role of cAMP receptor in tumor growth as well.
- the precise role of RI.sub. ⁇ in cell proliferation is not known at present.
- RI.sub. ⁇ may suppress RII.sub. ⁇ production by titrating out C subunit, or it may be a transducer of mitogenic signals leading to cell proliferation.
- Our results demonstrate that RI.sub. ⁇ antisense oligodeoxynucleotide provides a useful genetic tool for studies on the role of cAMP receptor proteins in cell proliferation and differentiation, and contribute to a new approach in the control of malignancy.
- RI.sub. ⁇ antisense oligonucleotide having SEQ ID NO:1 was administered to mice having an experimental tumor.
- a pellet of RI.sub. ⁇ antisense oligonucleotide (25 mg/Kg) and cholesterol (1000 mg/Kg) was implanted s.c. in the left flank of athymic mice which had been injected in the right flank with LS-174T human colon cancer cells (2 ⁇ 10 6 cells) suspended in phosphate-buffered saline.
- Tumor measurements and mouse weights were recorded on the initial day of treatment (staging day), and at the end of treatment (staging day +5).
- the mean tumor weight change ( ⁇ ) was based on length and width measurements in millimeters. After a few days, the tumor growth was inhibited when compared to control cells (see Table 3). No change in body weight was noted in the control and treated animals.
- the RI.sub. ⁇ antisense oligonucleotide having SEQ ID NO: 1 was added to dishes containing neuroblastoma, colon carcinoma, breast carcinoma and gastric carcinoma cells. As shown in FIG. 5, the RI.sub. ⁇ antisense oligonucleotide having SEQ ID No: 1 inhibited proliferation of all cancer cell types when compared to control cells. Moreover, the RI.sub. ⁇ antisense oligonucleotide having SEQ ID No: 1 caused differentiation of the human neuroblastoma cells (see FIG. 6).
- the oligomers had the following sequences: RI.sub. ⁇ antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3' (SEQ ID NO:1); RII.sub. ⁇ antisense, 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3'; and random oligo, 5'-CGA-TCG-ATC-GAT-CGA-TCG-TAC-3'.
- LS-174T human colon carcinoma cells (2 ⁇ 10 6 ) were injected s.c. in athymic mice, and the antisense oligodeoxynucleotides in the form of either a cholesterol pellet or 50% sesame oil emulsion were administered s.c. 1 week later when mean tumor sizes usually were 25-50 mg.
- FIG. 7 shows the dose- and time-dependent effect of an RI.sub. ⁇ antisense oligodeoxynucleotide (O-oligo) at 0.2 and 0.5 mg doses in cholesterol pellets administered s.c. one time (at zero time); it brought about 20 and 46% growth inhibition, respectively, in 7 days when compared with control (untreated) tumors (FIG. 7A).
- the RI.sub. ⁇ antisense phosphorothioate analog (S-oligo) at a 0.2 mg dose cholesterol pellet, s.c.
- RI.sub..sub. ⁇ antisense S-oligo brought about no apparent toxicity in animals; no body weight loss or other toxic symptoms were observed during the 3 weeks of treatment.
- RI.sub. ⁇ antisense S-oligo was the specific effect of the oligomer: RII.sub. ⁇ antisense or random (mismatched sequence) S-oligos of the identical size as the RI.sub. ⁇ antisense oligomer had no effect on the tumor growth (FIG. 7B).
- RI.sub. ⁇ levels were determined by immunoblotting (Ally, S., Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988)) using monoclonal antibody against human RI.sub. ⁇ (kindly provided by Drs. T. Lea, University of Oslo, Oslo, Norway, and S. O.
- RII.sub. ⁇ was measured by immunoprecipitation (Tortora, G., et al., Proc. Natl. Acad. Sci. USA 87:705-708 (1990)) with anti-RII.sub. ⁇ antiserum (kindly provided by Dr. S. O. D.o slashed.skeland) after photoaffinity labeling of RII.sub. ⁇ with 32 P! 8-N 3 -cAMp.
- RI.sub. ⁇ antisense S-oligomer treatment brought about a marked reduction (80% decrease) of RI.sub. ⁇ level in tumors as compared with that in untreated control tumors.
- This suppression of RI.sub. ⁇ expression by RI.sub. ⁇ antisense S-oligomer brought about a 2-fold increase in RII.sub. ⁇ level (Table 4).
- Such coordinated expression of RI.sub. ⁇ and RII.sub. ⁇ without changes in the amount of catalytic subunit of protein kinase has been shown in HL-60 leukemia cells that demonstrated growth inhibition and differentiation upon exposure to RI.sub. ⁇ antisense oligodeoxynucleotide.
- cAMP transduces signals for dual control, either positive or negative, on cell proliferation, depending on the availability of RI.sub. ⁇ or RII.sub. ⁇ receptor proteins.
- the RI.sub. ⁇ antisense oligodeoxynucleotide which suppressed RI.sub. ⁇ and enhanced RII.sub. ⁇ expression, led to inhibition of in vivo growth of solid colon carcinoma in athymic mice with no symptoms of toxicity in animals.
- the phosphorothioate analog (S-oligo) of RI.sub. ⁇ antisense oligomer exhibited a greater potency than the antisense of unmodified oligodeoxynucleotide (O-oligo).
- Seq ID No: 1 represents an antisense sequence corresponding to the first 7 N-terminal codons for RI.sub. ⁇ .
- Seq ID No: 2 represents an antisense sequence corresponding to the 8 th -13 th codon for RI.sub. ⁇ .
- Seq ID No: 3 represents an antisense sequence corresponding to the 14 th -20 th codon for RI.sub. ⁇ .
- Seq ID No: 4 represents an antisense sequence corresponding to the 94 th -100 th codon for RI.sub. ⁇ .
- Seq ID No: 5 represents an antisense sequence corresponding to the 1 st -100 th codon for RI.sub. ⁇ .
- Seq ID No: 6 represents the sense sequence corresponding to the 1 st -100 th codon for RI.sub. ⁇ .
Abstract
Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP-dependent protein kinases are disclosed along with pharmaceutical compositions containing these oligonucleotides as the active ingredients. These antisense oligonucleotides are useful for inhibiting the growth of cancer.
Description
This application is a continuation of Appl. Ser. No. 08/060,984, filed May 14, 1993, which is a divisional of Appl. Ser. No. 07/702,163, filed May 20, 1991, which issued on Dec. 21, 1993 as U.S. Pat. No. 5,271,941, which is a continuation-in-part of Appl. Ser. No. 07/680,198, filed Apr. 5, 1991, abandoned, which is a continuation-in-part of Appl. Ser. No. 07/607,113, filed Nov. 2, 1990, abandoned.
The invention is in the field of medicinal chemistry. In particular, the invention relates to certain antisense oligonucleotides and the use thereof for the treatment of cancer.
The present invention was made with government support. Accordingly, the United States government has certain rights in the invention.
Control mechanisms for cell growth and differentiation are disrupted in neoplastic cells (Potter, V. R. (1988) Adv. Oncol. 4, 1-8; Strife, A. & Clarkson, B. (1988) Semin. Hematol. 25, 1-19; Sachs, L. (1987) Cancer Res. 47, 1981-1986). cAMP, an intracellular regulatory agent, has been considered to have a role in the control of cell proliferation and differentiation (Pastan, I., Johnson, G. S. & Anderson, W. B. (1975) Ann. Rev. Biochem. 44, 491-522; Prasad, K. N. (1975) Biol. Rev. 50, 129-165; Cho-Chung, Y. S. (1980) J. Cyclic Nucleotide Res. 6, 163-177; Puck, T. T. (1987) Somatic Cell Mot. Genet. 13, 451-457). Either inhibitory or stimulatory effects of cAMP on cell growth have been reported previously in studies in which cAMP analogs such as N6 -O2' -dibutyryladenosine 3',5'-cyclic monophosphate or agents that raise intracellular cAMP to abnormal and continuously high levels were used, and available data are interpreted very differently (Chapowski, F. J., Kelly, L. A. & Butcher, R. W. (1975) Adv. Cyclic Nucleotide Protein Phosphorylat. Res. 6, 245-338; Cho-Chung, Y. S. (1979) in Influence of Hormones on Tumor Development, eds. Kellen, J. A. & Hilf, R. (CRC, Boca Raton, Fla.), pp. 55-93); Prasad, K. N. (1981) in The Transformed Cell, eds. Cameron, L. L. & Pool, T. B. (Academic, New York), pp. 235-266; Boynton, A. L. & Whitfield, J. F. (1983) Adv. Cyclic Nucleotide Res. 15, 193-294).
Recently, site-selective cAMP analogs were discovered which show a preference for binding to purified preparations of type II rather than type I cAMP-dependent protein kinase in vitro (Robinson-Steiner, A. M. & Corbin, J. D. (1983) J. Biol. chem. 258, 1032-1040; .O slashed.greid, D., Ekanger, R., Suva, R. H., Miller, J. P., Sturm, P., Corbin, J. D. & D.o slashed.skeland, S. O. (1985) Eur. J. Biochem. 150, 219-227), provoke potent growth inhibition, differentiation, and reverse transformation in a broad spectrum of human and rodent cancer cell lines (Katsaros, D., Tortora, G., Tagliaferri, P., Clair, T., Ally, S., Neckers, L., Robins, R. K. & Cho-Chung, Y. S. (1987) FEBS Lett. 223, 97-103; Tortora, G., Tagliaferri, P., Clair, T., Colamonici, O., Neckers, L. M., Robins, R. K. & Cho-Chung, Y. S. (1988) Blood, 71, 230-233; Tagliaferri, P., Katsaros, D., Clair, T., Robins, R. K. & Cho-Chung, Y. S. (1988) J. Biol. Chem. 263, 409-416). The type I and type II protein kinases are distinguished by their regulatory subunits (RI and RII, respectively) (Corbin, J. D., Keely, S. L. & Park, C. R. (1975) J. Biol. Chem. 250, 218-225; Hofmann, F., Beavo, J. A. & Krebs, E. G. (1975) J. Biol. Chem. 250, 7795-7801). Four different regulatory subunits RI.sub.α (previously designated RI) (Lee, D. C., Carmichael, D. F., Krebs, E. G. & McKnight, G. S. (1983) Proc. Natl. Acad. Sci. USA 80, 3608-3612) , RI.sub.β (Clegg, C. H., Cadd, G. G. & McKnight, G. S. (1988) Proc. Natl. Acad. Sci. USA 85, 3703-3707), RII.sub.α (RII54) (Scott, J. D., Glaccum, M. B., Zoller, M. J., Uhler, M. D., Hofmann, D. M., McKnight, G. S. & Krebs, E. G. (1987) Proc. Natl. Acad. Sci. USA 84, 5192-5196) and RII.sub.β (RII51) (Jahnsen, T., Hedin, L., Kidd, V. J., Beattie, W. G., Lohmann, S. M., Walter, U., Durica, J., Schulz, T. Z., Schlitz, E., Browner, M., Lawrence, C. B., Goldman, D., Ratoosh, S. L. & Richards, J. S. (1986) J. Biol. Chem. 261, 12352-12361)! have now been identified at the gene/mRNA level. Two different catalytic subunits C.sub.α (Uhler, M. D., Carmichael, D. F., Lee, D. C. Chrivia, J. C., Krebs, E. G. & McKnight, G. S. (1986) Proc. Natl. Acad. Sci. USA 83, 1300-1304) and C.sub.β (Uhler, M. D., Chrivia, J. C. & McKnight, G. S. (1986) J. Biol. Chem. 261, 15360-15363; Showers, M. O. & Maurer, R. A. (1986) J. Biol. Chem. 261, 16288-16291) ! have also been identified; however, preferential coexpression of either one of these catalytic subunits with either the type I or type II protein kinase regulatory subunit has not been found ( Showers, M. O. & Maurer, R. A. (1986) J. Biol. Chem. 261, 16288-16291).
The growth inhibition by site-selective cAMP analogs parallels reduction in RI.sub.α with an increase in RII.sub.β, resulting in an increase of the RII.sub.β /RI.sub.α ratio in cancer cells (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., .O slashed.greid, D., D.o slashed.skeland, S. O., Jahnsen, T. & Cho-Chung, Y. S. (1988) Proc. Natl. Acad. Sci. USA 85, 6319-6322; Cho-Chung, Y. S. (1989) J. Natl. Cancer Inst. 81, 982-987).
Such selection modulation of RI.sub.α versus RII.sub.β is not mimicked by treatment with N6,O2' -dibutyryladeno-sine 3',5'-cyclic monophosphate, a previously studied cAMP analog (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., .O slashed.greid, D., D.o slashed.skeland, S. O., Jahnsen, T. & Cho-Chung, Y. S. (1988) Proc. Natl. Acad. Sci. USA 85, 6319-6322). The growth inhibition further correlates with a rapid translocation of RII.sub.β to the nucleus and an increase in the transcription of the RII.sub.β gene (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., .O slashed.greid, D., D.o slashed.skeland, S. O., Jahnsen, T. & Cho-Chung, Y. S. (1988) Proc, Natl. Acad, Sci. USA 85, 6319-6322). These results support the hypothesis that RII.sub.β plays an important role in the cAMP growth regulatory function (Cho-Chung, Y. S. (1989) J. Natl. Cancer Inst. 81, 982-987).
Antisense RNA sequences have been described as naturally occurring biological inhibitors of gene expression in both prokaryotes (Mizuno, T., Chou, M-Y, and Inouye, M. (1984), Proc. Natl. Acad. Sci. USA 81, (1966-1970)) and eukaryotes (Heywood, S. M. Nucleic Acids Res., 14, 6771-6772 (1986)), and these sequences presumably function by hybridizing to complementary mRNA sequences, resulting in hybridization arrest of translation (Paterson, B. M., Roberts, B. E., and Kuff, E. L., (1977) Proc. Natl. Acad. Sci. USA, 74, 4370-4374. Antisense oligodeoxynucleotides are short synthetic nucleotide sequences formulated to be complementary to a specific gene or RNA message. Through the binding of these oligomers to a target DNA or mRNA sequence, transcription or translation of the gene can be selectively blocked and the disease process generated by that gene can be halted. The cytoplasmic location of mRNA provides a target considered to be readily accessible to antisense oligodeoxynucleotides entering the cell; hence much of the work in the field has focused on RNA as a target. Currently, the use of antisense oligodeoxynucleotides provides a useful tool for exploring regulation of gene expression in vitro and in tissue culture (Rothenberg, M., Johnson, G., Laughlin, C., Green, I., Craddock, J., Sarver, N., and Cohen, J. S. (1989) J. Natl. Cancer Inst., 81:1539-1544.
The invention is related to the discovery that inhibiting the expression of RI.sub.α in leukemia cells by contact with an antisense O-oligonucleotides and S-oligonucleotides for RI.sub.α results in the inhibition of proliferation and the stimulation of cell differentiation. Accordingly, the invention is directed to RI.sub.α antisense oligonucleotides and pharmaceutical compositions thereof for the treatment of cancer.
In particular, the invention is related to 15- to 30-mer antisense oligonucleotides which are complementary to a region in the first 100 N-terminal codons of RI.sub.α (Seq. ID No:6).
The invention is also related to 15- to 30-mer antisense oligonucleotides which are a fragment of antisense DNA complementary to RI.sub.α (Seq. ID No: 5).
The invention is also related to pharmaceutical compositions comprising at least one 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI.sub.α (Seq. ID No:6); and a pharmaceutically acceptable carrier.
The invention is also related to a method for treating cancer by suppressing growth of cancer cells susceptible to growth suppression and for inducing cancer cell differentiation in an animal comprising administering to an animal in need of such treatment a cancer cell growth suppressing amount of an RI.sub.α antisense oligonucleotide.
FIGS. 1A and 1B depict a graph showing the effect of RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1) on the basal rate of growth of HL-60 leukemic cells (A) and the growth of these cells when treated with cAMP -analogs or TPA (B). A, cells were grown (see the Examples) in the absence (∘) or presence () of RI.sub.α antisense oligodeoxynucleotide (15 μM). At indicated times, cell counts in duplicate were performed. Data represent the average values±SD of four experiments. B, On day 4 of experiment A, cells exposed or unexposed to RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1) were reseeded (day 0) at 5×105 cells/dish, and cells pre-exposed to RI.sub.α antisense oligodeoxynucleotide were further treated with the oligomer at day 0 and day 2. cAMP analogs and TPA were added one time at day 0. Cell counts were performed on a Coulter counter on day 4. 8-Cl, 8-Cl-cAMP (10 μM); 8-C1+N6 -B, 8-C1-cAMP (5 μM)+N6 -benzyl-cAMP (5 μM); TPA (10-8 M). The data represent the average values±SD of four experiments.
FIGS. 2A, 2B, 2C, 2D, 2E and 2F depict the effect of RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1) on the morphologic transformation of HL-60 cells. Cells either exposed or unexposed to RI.sub.α antisense oligodeoxynucleotide were treated with cAMP analogs or TPA as described in FIG. 1B. On day 4 (see FIG. 1B), cells were washed twice in Dulbecco's phosphate-buffered saline and were pelleted onto a glass slide by cytocentrifuge. The resulting cytopreparations were fixed and stained by Wright's stain.×180.
FIGS. 3A and 3B depict a Northern blot showing decreased RI.sub.α mRNA expression in HL-60 leukemic cells exposed to RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1). Cells were either exposed or unexposed to RI.sub.α antisense oligodeoxynucleotide (15 μM) for 8 hr. Isolation of total RNA and Northern blot analysis followed the methods described in the Examples. A, ethidium bromide staining of RNA; M, markers of ribosomal RNAs; lanes 1, 2, cells unexposed or exposed to RI.sub.α antisense oligomer. B, Northern blot analysis; the same nitrocellulose filter was hybridized to both RI.sub.α and actin probes in sequential manner. Lanes 1, 2, cells unexposed or exposed to RI.sub.α antisense oligomer.
FIGS. 4A and 4B, and 4C depict an SDS-PAGE showing the effect of RI.sub.α antisense oligodeoxynucleotide on the basal and induced levels of RI.sub.α and RII.sub.β cAMP receptor proteins in HL-60 leukemic cells. Cells were either exposed to RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1) (15 μM) or treated with cAMP analogs as described in FIG. 1. Preparation of cell extracts, the photoactivated incorporation of 8-N3 - 32 P! cAMP and immunoprecipitation using the anti-RI.sub.α or anti-RII.sub.β antiserum and protein A Sepharose, and SDS-PAGE of solubilized antigen-antibody complex followed the methods described in the Examples. Pre-immune serum controls were carried out simultaneously and detected no immunoprecipitated band. M, 14 C-labeled marker proteins of known molecular weight; RI.sub.α, the 48,000 molecular weight RI (Sigma); RII.sub.α, the 56,000 molecular weight RII (Sigma). Lanes RI.sub.α and RII.sub.β are from photoaffinity labeling with 8-N3 - 32 P!cAMP only; lanes 1 to 3, photoaffinity labeling with 8-N3 - 32 P!cAMP followed by immunoprecipitation with anti-RI.sub.α or anti-RII.sub.β antiserum. 8-Cl, 8-Cl-cAMP (5 μM); N6 -benzyl,N6 -benzyl-cAMP (5 μM). The data in the table represent quantification by densitometric scanning of the autoradiograms. The data are expressed relative to the levels in control cells unexposed to RI.sub.α antisense oligomer and untreated with cAMP analog, which are set equal to 1 arbitrary unit. The data represent an average±SD of three experiments. A and B, immunoprecipitation with anti-RI.sub.α and anti-RII.sub.β antisera, respectively.
FIGS. 5A, 5B, 5C and 5D depict graphs showing the growth inhibition of human cancer cell lines by RI.sub.α antisense oligodeoxynucleotide having SEQ ID No: 1 (O-oligo and S-oligo derivatives), compared to controls. Cell lines: SK-N-SH, neuroblastoma; LS-174T, colon carcinoma; MCF-7, breast carcinoma; TMK-1, gastric carcinoma. E2, estradiol-17β.
FIGS. 6A, 6B, and 6C depict the change in morphology of SK-N-SH human neuroblastoma cells exposed to RI.sub.α antisense oligodeoxynucleotide having SEQ ID No: 1.
FIGS. 7A and 7B depict a graph showing that RI.sub.α antisense oligodeoxynucleotide and its phosphorothioate analog (SEQ ID NO:1) inhibit the in vivo growth of LS-174T human colon carcinoma in athymic mice. FIG. 7A shows the oligodeoxynucleotide concentration-dependent inhibition of tumor growth. O-oligo, RI.sub.α antisense oligodeoxynucleotide; S-oligo, phosphorothioate analog of RI.sub.α antisense oligomer. The cholesterol pellets (total weight 20 mg) containing the indicated doses of O-oligo or S-oligo were implanted s.c. one time, at zero time, and tumor sizes were measured. Tumor volume (see Materials and Methods, Example 3) represents an average±S.D. of 7 tumors. FIG. 7B shows the temporal effect of antisense oligodeoxynucleotide phosphorothioate analogs on tumor growth. S-oligos as indicated at 0.3 mg dose in cholesterol pellets (total weight 20 mg) were implanted s.c. 2×/week, and tumor volume (see Materials and Methods, Example 3) represents an average±S.D. of 7 tumors.
Antisense therapy is the administration of exogenous oligonucleotides which bind to a target polynucleotide located within the cells. The term "antisense" refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., RI.sub.α. See for example, Jack Cohen, OLIGODEOXYNUCLEOTIDES, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The RI.sub.α antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, supra) which exhibit enhanced cancer cell growth inhibitory action (see FIGS. 5 and 7A).
S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention may be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide which is a sulfur transfer reagent. See Iyer, R. P. et al, J. Org. Chem. 55:4693-4698 (1990); and Iyer, R. P. et al., J. Am. Chem. Soc. 112:1253-1254 (1990), the disclosures of which are fully incorporated by reference herein.
The RI.sub.α antisense oligonucleotides of the present invention may be RNA or DNA which is complementary to and stably hybridizes with the first 100 N-terminal codons of the RI.sub.α genome or the corresponding mRNA. Use of an oligonucleotide complementary to this region allows for the selective hybridization to RI.sub.α mRNA and not to mRNA specifying other regulatory subunits of protein kinase. Preferably, the RI.sub.α antisense oligonucleotides of the present invention are a 15 to 30-mer fragment of the antisense DNA molecule having SEQ ID NO:5 which hybridizes to RI.sub.α mRNA. Alternatively, RI.sub.α antisense oligonucleotide is a 15- to 30-mer oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI.sub.α (Seq. ID No:6). Most preferably, the RI.sub.α antisense oligonucleotide has SEQ ID No:1, SEQ ID No:2, SEQ ID No:3, or SEQ ID No:4.
Included as well in the present invention are pharmaceutical compositions comprising an effective amount of at least one of the RI.sub.α antisense oligonucleotides of the invention in combination with a pharmaceutically acceptable carrier. In one embodiment, a single RI.sub.α antisense oligonucleotide is utilized. In another embodiment, two RI.sub.α antisense oligonucleotides are utilized which are complementary to adjacent regions of the RI.sub.α genome. Administration of two RI.sub.α antisense oligonucleotides which are complementary to adjacent regions of the RI.sub.α genome or corresponding mRNA may allow for more efficient inhibition of RI.sub.α genomic transcription or mRNA translation, resulting in more effective inhibition of cancer cell growth.
Preferably, the RI.sub.α antisense oligonuoleotide is coadministered with an agent which enhances the uptake of the antisense molecule by the cells. For example, the RI.sub.α antisense oligonucleotide may be combined with a lipophilic cationic compound which may be in the form of liposomes. The use of liposomes to introduce nucleotides into cells is taught, for example, in U.S. Pat. Nos. 4,897,355 and 4,394,448, the disclosures of which are incorporated by reference in their entirety. See also U.S. Pat. Nos. 4,235,871, 4,231,877, 4,224,179, 4,753,788, 4,673,567, 4,247,411, 4,814,270 for general methods of preparing liposomes comprising biological materials.
Alternatively, the RI.sub.α antisense oligonucleotide may be combined with a lipophilic carrier such as any one of a number of sterols including cholesterol, cholate and deoxycholic acid. A preferred sterol is cholesterol.
In addition, the RI.sub.α antisense oligonucleotide may be conjugated to a peptide that is ingested by cells. Examples of useful peptides include peptide hormones, antigens or antibodies, and peptide toxins. By choosing a peptide that is selectively taken up by the neoplastic cells, specific delivery of the antisense agent may be effected. The RI.sub.α antisense oligonucleotide may be covalently bound via the 5'OH group by formation of an activated aminoalkyl derivative. The peptide of choice may then be covalently attached to the activated RI.sub.α antisense oligonucleotide via an amino and sulfhydryl reactive hereto bifunctional reagent. The latter is bound to a cysteine residue present in the peptide. Upon exposure of cells to the RI.sub.α antisense oligonucleotide bound to the peptide, the peptidyl antisense agent is endocytosed and the RI.sub.α antisense oligonucleotide binds to the target RI.sub.α mRNA to inhibit translation. See PCT Application Publication No. PCT/US89/02363.
As antineoplastic agents, the RI.sub.α antisense oligonucleotides of the present invention are useful in treating a variety of cancers, including, but not limited to, gastric, pancreatic, lung, breast, anal, colorectal, head and neck neoplasms, neuroblastomas, melanoma and various leukemias.
The RI.sub.α antisense oligonucleotides of the invention may also be active against the following tumor systems: F9 teratocarcinoma, SK-N-SH neuroblastoma, TMK-1 gastric carcinoma, HL-60 promyelocytic Leukemia, Leukemia L-1210, Leukemia P388, P1534 leukemia, Friend Virus Leukemia, Leukemia L4946, Mecca lymphosarcoma, Gardner lymphosarcoma, Ridgway Osteogenic sarcoma, Sarcoma 180 (ascites), Wagner osteogenic sarcoma, Sarcoma T241, Lewis lung carcinoma, Carcinoma 755, CD8F, MCF-7 breast carcinoma, Colon 38, LS-174T colon carcinoma, Carcinoma 1025, Ehrlich carcinoma (ascites & solid), Krubs 2 carcinoma (ascites), Bashford carcinoma 63, Adenocarcinoma E 0771, B16 Melanoma, Hardin-Passey melanoma, Giloma 26, Miyona adenocarcinoma, Walker carcinosarcoma 256, Flexner-Jobling carcinoma, Jensen sarcoma, Iglesias sarcoma, Iglesias ovarian tumor, Murphy-Sturn lymphosarcoma, Yoshida sarcoma, Dunning leukemia, Rous chicken sarcoma, and Crabb hamster sarcoma.
The RI.sub.α antisense oligonucleotides and the pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intra-peritoneal, or transdermal routes. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
Compositions within the scope of this invention include all compositions wherein the RI.sub.α antisense oligonucleotide is contained in an amount which is effective to achieve inhibition of proliferation and/or stimulate differentiation of the subject cancer cells. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill in the art. Typically, the RI.sub.α antisense oligonucleotide may be administered to mammals, e.g. humans, at a dose of 0.005 to 1 mg/kg/day, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated.
In addition to administering the RI.sub.α antisense oligonucleotides as a raw chemical in solution, the RI.sub.α antisense oligonucleotides may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the RI.sub.α antisense oligonucleotide into preparations which can be used pharmaceutically.
Suitable formulations for parenteral administration include aqueous solutions of the RI.sub.α antisense oligonucleotides in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl cleats or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.
The antisense oligonucleotides of the present invention may be prepared according to any of the methods that are well known to those of ordinary skill in the art. Preferably, the antisense oligonucleotides are prepared by solid phase synthesis. See, Goodchild, J., Bioconjugate Chemistry, 1:165-167 (1990), for a review of the chemical synthesis of oligonucleotides. Alternatively, the antisense oligonucleotides can be obtained from a number of companies which specialize in the custom synthesis of oligonucleotides.
Having now generally described this invention, the same will be understood by reference to an example which is provided herein for purposes of illustration only and is not intending to be limited unless otherwise specified. The entire text of all applications, patents and publications, if any, cited above and below are hereby incorporated by reference.
Oligodeoxynucleotides
The 21-mer oligodeoxynucleotides used in the present studies were synthesized at Midland Certified Reagent Co. (Midland, Tex.) and had the following sequences: human RI.sub.α (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) Biochem. Biophys. Res. Commun. 149, 939-945) antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3' (SEQ ID No:1); human RII.sub.β (Levy, F. O., Oyen, O., Sandberg, M., Tasken, K., Eskild, W., Hansson, V. & Jahnsen, T. (1988) Mol. Endocrinol., 2, 1364-1373) antisense 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3',; human RII.sub.α (Oyen, O., Myklebust, F., Scott, J. D., Hansson, V. & Jahnsen, T. (1989) FEBS Lett. 246, 57-64) antisense, 5'-CGG-GAT-CTG-GAT-GTG-GCT-CAT-3'; and the random sequence oligodeoxynucleotide was made of a mixture of all four nucleotides at every position.
Cell Growth Experiment
Cells grown in suspension culture in RPM1 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 U/ml), streptomycin (500 μg/ml), and 1 mM glutamine (Gibco, Grand Island, N.Y.) were seeded at 5×105 cells per dish. Oligodeoxynucleotides were added after seeding and every 48 hr thereafter. Cell counts were performed on a Coulter counter. Cells unexposed or exposed to oligodeoxynucleotides for 4 days were reseeded (day 0) at 5×105 cells/dish, and cells pre-exposed to the oligodeoxynucleotide were further treated with the oligomer at day 0 and day 2. cAMP analogs (kindly provided by Dr. R. K. Robins, Nucleic Acid Research Institute, Costa Mesa, Calif.) or 12-O-tetradecanoylphorbol-13-acetate (TPA) were added one time at day 0. Cell counts were performed on day 4.
Immunoprecipitation of RI.sub.α and RII.sub.β cAMP Receptor Proteins after Photoaffinity Labeling with 8-N3 - 32 P!cAMP.
Cell extracts were prepared at 0°-4° C. The cell pellets (2×106 cells), after two washes with PBS, were suspended in 0.5 ml buffer Ten (0.1M NaCl, 5 mM MgCl2, 1% Nonidet P-40, 0.5% Na deoxycholate, 2 KIU/ml bovine aprotinin, and 20 mM Tris-HCl, pH 7.4) containing proteolysis inhibitors (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708), vortex-mixed, passed through a 22-gauge needle 10 times, allowed to stand for 30 min at 4° C., and centrifuged at 750×g for 20 min; the resulting supernatants were used as cell lysates. The photoactivated incorporation of 8-N3 - 32 P!cAMP (60.0 Ci/mmol), and the immunoprecipitation using the anti-RI.sub.α or anti-RII.sub.β antiserum (kindly provided by Dr. S. O. D.o slashed.skeland, .University of Bergen, Bergen, Norway) and protein A Sepharose and SDS-PAGE of solubilized antigen-antibody complex followed the method previously described (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708; Ekanger, R., Sand, T. E., Ogreid, D., Christoffersen, T. & D.o slashed.skeland, S. O. (1985) J. Biol. Chem. 260, 3393-3401).
cAMP-Dependent Protein Kinase Assays
After two washes with Dulbecco's phosphate-buffered saline, cell pellets (2×106 cells) were lysed in 0.5 ml of 20 mM Tris (pH 7.5), 0.1 mM sodium EDTA, 1 mM dithiothreitol, 0.1 mM pepstatin, 0.1 mM antipain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.4 mg/ml aprotinin, and 0.5 mg/ml soybean trypsin inhibitor, using 100 strokes of a Dounce homogenizer. After centrifugation (Eppendorf 5412) for 5 min, the supernatants were adjusted to 0.7 mg protein/ml and assayed (Uhler, M. D. & McKnight, G. S. (1987) J. Biol. Chem. 262, 15202-15207) immediately. Assays (40 μl total volume) were performed for 10 min at 30° C. and contained 200 μM ATP, 2.7×106 cpm γ 32 P!ATP, 20 mM MgCl2, 100 μM Kemptide (Sigma K-1127) (Kemp, B. E., Graves, D. J., Benjamin, E. & Krebs, E. G. (1977) J. Biol. Chem. 252, 4888-4894), 40 mM Tris (pH 7.5), ±100 μM protein kinase inhibitor (Sigma P-3294) (Cheng, H.-C., Van Patten, S. M., Smith, A. J. & Walsh, D. A. (1985) Biochem. J. 231, 655-661), ±8 μM cAMP and 7 μg of cell extract. The phosphorylation of Kemptide was determined by spotting 20 μl of incubation mixture on phosphocellulose filters (Whatman, P81) and washing in phosphoric acid as described (Roskoski, R. (1983) Methods Enzymol. 99, 3-6). Radioactivity was measured by liquid scintillation using Econofluor-2 (NEN Research Products NEF-969).
Isolation of Total RNA and Northern Blot Analysis
The cells (108 washed twice with phosphate-buffered saline) were lysed in 4.2M guanidine isothiocyanate containing 25 mM sodium citrate (pH 7.0), 0.5% sarcosyl (N-lauroylsarcosine Na+), and 0.1M β-mercaptoethanol, and the lysates were homogenized, and total cellular RNA was sedimented through a CsCl cushion (5.7M CsCl, 10 mM EDTA) as described by Chirgwin et al. (Chirgwin, J. M., Przybyla, A. E., MacDonald, R. Y. & Rutter, W. J. (1977) Biochemistry 18, 5284-5288). Total cellular RNA containing 20 mM 3- N-morpholine!propane-sulfonic acid (pH 7.0), 50% formamide, and 6% formaldehyde was denatured at 65° C. for 10 min and electrophoresed through a denaturing 1.2% agarose-2.2M formaldehyde gel. The gels were then transferred to Biotrans nylon membranes (ICN Biomedicals) by the method of Thomas (Thomas, P. S. (1980) Proc. Natl. Acad. Sci. USA 77, 5201-5205) and hybridized to the following two 32 P-labeled nick-translated CDNA probes: 1.5 kilobase (kb) cDNA clone containing the entire coding region for the human cAMP-dependent protein kinase type I regulatory subunit, RI.sub.α (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) Biochem. Biophys. Res. Commun. 149, 939-945) (kindly provided by Dr. T. Jahnsen, Institute of Pathology, Rikshospitalet, Oslo, Norway), and human β actin (Oncor p7000 β actin).
RESULTS
The RI.sub.α antisense oligodeoxynucleotide at 15 μM concentration had immediate effects on the rate of proliferation of HL-60 cells. By 4-5 days in culture, while cells unexposed to RI.sub.α antisense oligomer demonstrated an exponential rate of growth, cells exposed to the antisense oligomer exhibited a reduced growth rate and eventually stopped replicating (FIG. 1A). This inhibitory effect on cell proliferation persisted throughout the culture period. The growth inhibition was not due to cell killing; cells were over 90% viable after exposure to RI.sub.α antisense oligomer (15 μM) for 7 days as assessed by flow cytometry using forward and side scatter. RI.sub.α sense, RII.sub.α, or RII.sub.β antisense, or a random sequence oligodeoxynucleotide had no such growth inhibitory effect.
Cells unexposed or exposed to RI.sub.α antisense oligodeoxynucleotide for 4 days in culture were reseeded and examined for their response to treatment with cAMP analogs or TPA. In cells unexposed to RI.sub.α antisense oligodeoxynucleotide, 8-C1-cAMP (10 μM) produced 60% growth inhibition, and 80% growth inhibition was achieved by 8-Cl-cAMP (5 μM) plus N6 -benzyl-cAMP (5 μM) (FIG. 1B) (Tortora, G., Tagliaferri, P., Clair, T., Colamonici, O. Neckers, L. M., Robins, R. K. & Cho-Chung, Y. S. (1988) Blood 71, 230-233), and TPA (10-8 M) exhibited 60% growth inhibition (FIG. 1B). In contrast, cells exposed to antisense oligodeoxynucleotide exhibited retarded growth (25% the rate of growth of cells unexposed to the antisense oligomer) and neither cAMP analogs nor TPA brought about further retardation of growth (FIG. 1B).
HL-60 cells undergo a monocytic differentiation upon treatment withsite-selective cAMP analogs. Cells either unexposed or exposed to RI.sub.α antisense oligodeoxynucleotide were examined for their morphology before and after treatment with cAMP analogs. As shown in FIG. 2, in cells unexposed to RI.sub.α antisense oligomer, 8-Cl-cAMP plus N6 -benzyl-cAMP induced a monocytic morphologic change characterized by a decrease in nuclear-to-cytoplasm ratio, abundant ruffled and vacuolated cytoplasm, and loss of nucleoli. Strikingly, the same morphologic change was induced when cells were exposed to RI.sub.α antisense oligodeoxynucleotide (FIG. 2). Moreover, the morphologic changes induced by antisense oligomer were indistinguishable from that induced by TPA (FIG. 2).
To provide more evidence that the growth inhibition and monocytic differentiation induced in HL-60 cells exposed to the RI.sub.α antisense oligodeoxynucleotide were due to an intracellular effect of the oligomer, the RI.sub.α mRNA level was determined. As shown in FIG. 3, 3.0 kb RI.sub.α mRNA (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) Biochem. Biophys. Res. Commun. 149, 939-945) was virtually undetectable in cells exposed for 8 hr to RI.sub.α antisense oligodeoxynucleotide (FIG. 3B, lane 2), and the decrease in RI.sub.α mRNA was not due to a lower amount of total RNA as shown by the ethidium bromide staining (compare lane 2 with lane 1 of FIG. 3A). Conversely, an enhanced level of actin mRNA was detected in cells exposed to RI.sub.α antisense oligomer (FIG. 3B). Whether the increase in actin mRNA level represents changes in cytoskeletal structure is not known.
The levels of cAMP receptor proteins in these cells was then determined by immunoprecipitation using anti-RI.sub.α and anti-RII.sub.β antisera (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708; Ekanger, R., Sand, T. E., Ogreid, D., Christoffersen, T. & D.o slashed.skeland, S. O. (1985) J. Biol. Chem. 260, 3393-3401) after photoaffinity labeling of these receptor proteins with 8-N3 - 32 P!cAMP. In control cells, treatment with 8-C1-cAMP plus N6 -benzyl-cAMP brought about a 70% reduction in RI.sub.α with a 3-fold increase in RII.sub.β, resulting in a 10-fold increase in the ratio of RII.sub.β /RI.sub.α (FIG. 4) (Cho-Chung, Y. S. (1989) J. Natl. Cancer Inst. 81, 982-987). Exposure of these cells to RI.sub.α antisense oligodeoxynucleotide for 4 days brought about marked changes in both and RI.sub.α and RII.sub.β levels; an 80% reduction in RI.sub.α with a 5-fold increase in RII.sub.β resulted in a 25-fold increase in the ratio of RII.sub.β /RI.sub.α compared with that in control cells (FIG. 4). Since growth inhibition and differentiation were appreciable after 3-4 days of exposure to RI.sub.α antisense oligomer, the changing levels of RI.sub.α and RII.sub.β proteins appears to be an early event necessary for commitment to differentiation.
Data in FIG. 4 showed that suppression of RI.sub.α by the antisense oligodeoxynucleotide brought about a compensatory increase in RII.sub.β level. Such coordinated expression of RI and RII without changes in the amount of C subunit has been shown previously (Hofman, F., Bechtel, P. J. & Krebs, E. G. (1977) J. Biol. Chem. 252, 1441-1447; Otten, A. D. & Mcknight, G. S. (1989) J. Biol. Chem. 264, 20255-20260). The increase in RII.sub.β may be responsible for the differentiation induced in these cells after exposure to RI.sub.α antisense oligodeoxynucleotide. The increase in RII.sub.β mRNA or RII.sub.β protein level has been correlated with cAMP analog-induced differentiation in K-562 chronic myelocytic leukemic cells (Tortora, G., Clair, T., Katsaros, D., Ally, S., Colamonici, O., Neckers, L. M., Tagliaferri, P., Jahnsen, T., Robins, R. K. & Cho-Chung, Y. S. (1989) Proc. Natl. Acad. Sci. USA 86, 2849-2852) and in erythroid differentiation of Friend erythrocytic leukemic cells (Schwartz, D. A. & Rubin, C. S. (1985) J. Biol. Chem. 260, 6296-6303). In a recent report (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) Proc. Natl. Acad. Sci. USA 87, 705-708), we have provided direct evidence that RII.sub.β is essential for the cAMP-induced differentiation in HL-60 cells. HL-60 cells that were exposed to RII.sub.β antisense oligodeoxynucleotide became refractory to treatment with cAMP analogs and continued to grow.
The essential role of RII.sub.β in differentiation of HL-60 cells was further demonstrated when these cells were exposed to both RI.sub.α and RII.sub.β antisense oligodeoxynucleotides simultaneously. As shown in Table 1, RI.sub.α antisense oligodeoxynucleotide (SEQ ID NO:1)induced a marked increase in the expression of monocytic surface antigens Leu 15 (Landay, A., Gartland, L. & Clement, L. T. (1983) J. Immunol. 131, 2757-2761) and Leu M3 (Dimitriu-Bona, A., Burmester, G. R., Waters, S. J. & Winchester, R. J. (1983) J. Immunol. 130, 145-152)! along with a decrease in markers related to the immature myelogenous cells My9 (Talle, M. A., Rao, P. E., Westberg, E., Allegar, N., Makowski, M., Mittler, R. S. & Goldstein, G. (1983) Cell. Immunol. 78, 83.; Todd, R. F. III, Griffin, J. D., Ritz, J., Nadler, L. M. Abrams, T. & Schlossman, S. F. (1981) Leuk. Res. 5, 491)!. These changes in surface marker expression were abolished when cells were exposed simultaneously to both RI.sub.α and RII.sub.β antisense oligodeoxynucleotides (Table 1). RII.sub.α cAMP receptor was not detected in HL-60 cells (Cho-Chung, Y. S., Clair, T., Tagliaferri, P., Ally, S., Katsaros, D., Tortora, G., Neckers, L., Avery, T. L., Crabtree, G. W. & Robins, R. K. (1989) Cancer Invest. 7(2), 161-177), and RII.sub.α antisense oligodeoxynucleotide showed no interference with the effects of RI.sub.α antisense oligomer (Table 1).
Cells exposed to both RI.sub.α and RII.sub.β antisense oligodeoxynucleotides were neither growth inhibited nor differentiated regardless of cAMP analog treatment. We interpret these results to reflect the blockage of cAMP-dependent growth regulatory pathway. Cells under these conditions are no longer cAMP-dependent but survive and proliferate probably through an alternate pathway. Thus, suppression of both RI.sub.α and RII.sub.β gene expression led to an abnormal cellular growth regulation similar to that in mutant cell lines (Gottesman, M. M. (1980) Cell 22, 329-330), those that contain either deficient or defective regulatory subunits of cAMP-dependent protein kinase and are no longer sensitive to cAMP stimulus.
Our results demonstrated that cAMP transduces signals for dual controls, either positive or negative, on cell proliferation, depending on the availability of RI.sub.α or RII.sub.β receptor proteins. The RI.sub.α antisense oligodeoxynucleotide which brought about suppression of RI.sub.α along with enhancement of RII.sub.β expression led to terminal differentiation of HL-60 leukemia with no sign of toxicity.
It is unlikely that free C subunit increase in cells exposed to RI.sub.α antisense oligodeoxynucleotide was responsible for the differentiation, because cells exposed to RII.sub.β antisense or both RI.sub.α and RII.sub.β antisense oligodeoxynucleotides, conditions which also would produce free C subunit, continued to grow and became refractory to cAMP stimulus. In order to directly verify this we measured phosphotransferase activity in cells that are exposed or unexposed to the antisense oligodeoxynucleotides using kemptide (Kemp, B. E., Graves, D. J., Benjamin, E. & Krebs, E. G. (1977) J. Biol. Chem. 252, 4888-4894) as a substrate in the presence and absence of a saturating concentration of cAMP and in the presence and absence of the heat-stable protein kinase inhibitor (Cheng, H.-C., Van Patten, S. M., Smith, A. J. & Walsh, D. A. (1985) Biochem. J. 231, 655-661). This method of assay gives accurate determination of the relative levels of dissociated C and total C activity. Cell extracts from untreated HL-60 cells exhibited a very low level of dissociated C and were stimulated 36-fold by cAMP (Table 2). This cAMP-stimulated activity was almost completely inhibited by the heat-stable protein kinase inhibitor (Table 2), indicating that the total C activity measured was cAMP-dependent protein kinase. In cells exposed to RI.sub.α antisense, RII.sub.β antisense, or RI.sub.α and RII.sub.β antisense oligodeoxynucleotide, the free C activity was not increased as compared to unexposed control cells, although there was a small difference in the total cAMP-stimulated activity (Table 2). These results provide direct evidence that free catalytic subunit is not responsible for the differentiation observed in HL-60 cells.
Over expression of RI.sub.α cAMP receptor protein has also been found in the majority of human breast and colon primary carcinomas examined (Bradbury, A. W., Miller, W. R., Clair, T., Yokozaki, H. & Cho-Chung, Y. S. (1990) Proc. Am. Assoc. Cancer Res. 31, 172), suggesting an important in vivo role of cAMP receptor in tumor growth as well. However, the precise role of RI.sub.α in cell proliferation is not known at present. RI.sub.α may suppress RII.sub.β production by titrating out C subunit, or it may be a transducer of mitogenic signals leading to cell proliferation. Our results demonstrate that RI.sub.α antisense oligodeoxynucleotide provides a useful genetic tool for studies on the role of cAMP receptor proteins in cell proliferation and differentiation, and contribute to a new approach in the control of malignancy.
TABLE 1 ______________________________________ Modulation of differentiation markers in HL-60 cells by RI.sub.α antisense oligodeoxynucleotide Surface Makers Treatment Leu15 LeuM3My9 ______________________________________ Control 10 2 100 RI.sub.α antisense 80 98 80 RI.sub.α antisense + RII.sub.β antisense 11 2 100 RII.sub.β antisense 13 3 100 RI.sub.α antisense + RII.sub.α antisense 85 100 80 ______________________________________
Surface antigen analysis was performed by flow cytometry using monoclonal antibodies reactive with either monocytic or myeloid cells. The monoclonal antibodies used were Leu 15, Leu M3, and My9. 2×104 cells were analyzed for each sample, and cell gating was performed using forward and side scatter. The numbers represent % positive and represent the average values of three experiments.
TABLE 2 ______________________________________ Protein kinase activity in HL-60 cells Relative Relative Stimula- Activity to Activity to tion Treatment -cAMP control +cAMP control (fold) ______________________________________ - PKI Control 23.0 ± 6.6 1.0 837 ± 87 1.0 36 RI.sub.α antisense 22.9 ± 5.4 1.0 944 ± 18 1.1 41 RII.sub.β antisense 22.8 ± 8.1 1.0 1,028 ± 154 1.2 45 RI.sub.α and 24.3 ± 7.0 1.1 802 ± 36 1.0 33 RII.sub.β antisense + PKI Control 17.5 ± 8.7 1.0 37.0 ± 8.4 1.0 2.1 RI.sub.α antisense 25.0 ± 8.8 1.4 22.6 ± 8.8 0.6 0.9 RII.sub.β antisense 24.0 ± 2.6 1.4 24.8 ± 3.9 0.7 1.0 RI.sub.α and 19.0 ± 5.9 1.1 19.1 ± 8.2 0.5 1.0 RII.sub.β antisense ______________________________________ Cells were exposed to each of 15 μM concentrations of RI.sub.α, RII.sub.β, or RI.sub.α and RII.sub.β antisense oligodeoxynucleotide for 4 days as shown in FIG. 1A. The data represent a average ± SD of duplicate determinations of three identical experiments. *Picomoles phosphate transferred to Kemptide per min/mg protein.
Next, the RI.sub.α antisense oligonucleotide having SEQ ID NO:1 was administered to mice having an experimental tumor. A pellet of RI.sub.α antisense oligonucleotide (25 mg/Kg) and cholesterol (1000 mg/Kg) was implanted s.c. in the left flank of athymic mice which had been injected in the right flank with LS-174T human colon cancer cells (2×106 cells) suspended in phosphate-buffered saline. Tumor measurements and mouse weights were recorded on the initial day of treatment (staging day), and at the end of treatment (staging day +5). The mean tumor weight change (Δ), was based on length and width measurements in millimeters. After a few days, the tumor growth was inhibited when compared to control cells (see Table 3). No change in body weight was noted in the control and treated animals.
TABLE 3 ______________________________________ Effect of RI.sub.α antisense oligodeoxynucleotide s.c. pellet on the growth of LS-174T human colon carcinoma in athymic mice Initial mean.sup.c Final mean.sup.d % tumor wt (mg) tumor wt (mg) ΔT/ΔC.sup.e ______________________________________ Treatment.sup.a s.c. pellet implanted Control 25 450 -- RI.sub.α antisense 25 230 48 (0.5 mg) 8-C1 cAMP (1 mg).sup.b + 34 250 51 N.sup.6 benzyl cAMP (1 mg) ______________________________________ .sup.a 20 mg pellet lyophilized consisting of indicated doses of RI.sub.α antisense or cAMP analogs plus supplement doses of cholesterol. .sup.b The growth inhibitory effect of these cAMP analogs correlate with decrease in RI.sub.α (Natl. Cancer Inst. 81 982 (1989)) and is shown here for comparison. .sup.c Mean tumor weight per group (4 mice) on staging day. .sup.d Mean tumor weight per group on staging day +5. .sup.e % of change in test tumor weight (ΔT)/change in control tumo weight (ΔC).
In other in vitro experiments, the RI.sub.α antisense oligonucleotide having SEQ ID NO: 1 was added to dishes containing neuroblastoma, colon carcinoma, breast carcinoma and gastric carcinoma cells. As shown in FIG. 5, the RI.sub.α antisense oligonucleotide having SEQ ID No: 1 inhibited proliferation of all cancer cell types when compared to control cells. Moreover, the RI.sub.α antisense oligonucleotide having SEQ ID No: 1 caused differentiation of the human neuroblastoma cells (see FIG. 6).
Next, the effect of O-oligo and S-oligo RI.sub.α antisense oligonucleotides on the growth of LS-174T human colon carcinoma in athymic mice was compared.
Materials and Methods
We synthesized Milligen Biosearch 8700 DNA synthesizer (Bedford, Mass.)! the 21-mer antisense oligodeoxynucleotides and their phosphorothioate analogs complementary to the human RI.sub.α, human RII.sub.β mRNA transcripts starting from the first codon, and mismatched sequence (random) oligomers of identical size. The oligomers had the following sequences: RI.sub.α antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3' (SEQ ID NO:1); RII.sub.β antisense, 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3'; and random oligo, 5'-CGA-TCG-ATC-GAT-CGA-TCG-TAC-3'.
LS-174T human colon carcinoma cells (2×106) were injected s.c. in athymic mice, and the antisense oligodeoxynucleotides in the form of either a cholesterol pellet or 50% sesame oil emulsion were administered s.c. 1 week later when mean tumor sizes usually were 25-50 mg. Tumor volume was based on length and width measurements and calculated by the formula 4/3 πr3, where r=(length+width)/4.
Results and Discussion
FIG. 7 shows the dose- and time-dependent effect of an RI.sub.α antisense oligodeoxynucleotide (O-oligo) at 0.2 and 0.5 mg doses in cholesterol pellets administered s.c. one time (at zero time); it brought about 20 and 46% growth inhibition, respectively, in 7 days when compared with control (untreated) tumors (FIG. 7A). Strikingly, the RI.sub.α antisense phosphorothioate analog (S-oligo) at a 0.2 mg dose (cholesterol pellet, s.c.) gave a 60% growth inhibition at day 7, exhibiting a 3-fold greater potency than the O-oligo antisense (FIG. 7A). The growth inhibitory effect of RI.sub..sub.α antisense S-oligo was even greater when animals were treated for a longer period. The RI.sub.α antisense S-oligo at a 0.3 mg dose in a cholesterol pellet, 2 times/week s.c. implantation for 3 weeks, resulted in a 80% growth inhibition; the tumor growth almost stopped after 2 weeks of treatment (FIG. 7B). RI.sub.α antisense O-oligo or S-oligo administered s.c. as 50% sesame oil emulsion gave similar results. RI.sub.α antisense S-oligo brought about no apparent toxicity in animals; no body weight loss or other toxic symptoms were observed during the 3 weeks of treatment.
The growth inhibitory effect brought about by RI.sub.α antisense S-oligo was the specific effect of the oligomer: RII.sub.β antisense or random (mismatched sequence) S-oligos of the identical size as the RI.sub.α antisense oligomer had no effect on the tumor growth (FIG. 7B).
To provide more evidence that the growth inhibition observed in colon carcinomas in athymic mice treated with RI.sub.α antisense oligodeoxynucleotide was due to an intracellular effect of the oligomer, the levels of RI.sub.α and RII.sub.β cAMP receptor proteins in these tumors were determined. RI.sub.α levels were determined by immunoblotting (Ally, S., Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988)) using monoclonal antibody against human RI.sub.α (kindly provided by Drs. T. Lea, University of Oslo, Oslo, Norway, and S. O. D.o slashed.skeland, University of Bergen, Bergen, Norway), and RII.sub.β was measured by immunoprecipitation (Tortora, G., et al., Proc. Natl. Acad. Sci. USA 87:705-708 (1990)) with anti-RII.sub.β antiserum (kindly provided by Dr. S. O. D.o slashed.skeland) after photoaffinity labeling of RII.sub.β with 32 P! 8-N3 -cAMp. As shown in Table 4, RI.sub.α antisense S-oligomer treatment brought about a marked reduction (80% decrease) of RI.sub.α level in tumors as compared with that in untreated control tumors. This suppression of RI.sub.α expression by RI.sub.α antisense S-oligomer brought about a 2-fold increase in RII.sub.β level (Table 4). Such coordinated expression of RI.sub.α and RII.sub.β without changes in the amount of catalytic subunit of protein kinase has been shown in HL-60 leukemia cells that demonstrated growth inhibition and differentiation upon exposure to RI.sub.α antisense oligodeoxynucleotide. On the other hand, a 50% increase in RI.sub.α level along with 80% suppression in RII.sub.β level was observed in tumors after treatment with RII.sub.β antisense S-oligomer (Table 4) which had no effect on tumor growth (FIG. 7). Random (mismatched sequence) S-oligomer which had no effect on tumor growth (FIG. 7) also showed no effect on RI.sub.α levels (Table 4). Thus, reduction in RI.sub.α expression appears to trigger a decrease or halt in tumor growth upon treatment with RI.sub.α antisense oligomer. Our results demonstrated that cAMP transduces signals for dual control, either positive or negative, on cell proliferation, depending on the availability of RI.sub.α or RII.sub.β receptor proteins. The RI.sub.α antisense oligodeoxynucleotide, which suppressed RI.sub.α and enhanced RII.sub.β expression, led to inhibition of in vivo growth of solid colon carcinoma in athymic mice with no symptoms of toxicity in animals. The phosphorothioate analog (S-oligo) of RI.sub.α antisense oligomer exhibited a greater potency than the antisense of unmodified oligodeoxynucleotide (O-oligo). It has been shown that S-oligos, as compared with O-oligos, more readily enter cells, are more resistant to endonucleases, and yet exhibit high efficacy in hybridization with target mRNAs or DNAs (Stein, C. A., et al., In: J. S. Cohen (ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, pp. 97-117. Boca Raton, Fla., CRC Press, Inc. (1989)).
These results demonstrate here for the first time the striking in vivo effect of antisense oligodeoxynucleotide in the suppression of malignancy. The depletion of RI.sub.α, the type I regulatory subunit of cAMP-dependent protein kinase, by means of an antisense oligodeoxynucleotide, especially with its phosphorothioate analog, leads to a successful halt of tumor growth in vivo with no symptoms of toxicity, suggesting great potential of this antisense oligodeoxynucleotide for clinical application.
TABLE 4 ______________________________________ Suppression of RI.sub.α cAMP Receptor Expression by RI.sub.α Antisense Oligodeoxynucleotide (S-oligo SEQ ID NO:1) Results in Compensatory Increase in RII.sub.α Receptor Relative Levels Treatment RI.sub.α RII.sub.β ______________________________________ None 1.0 ± 0.1 1.0 ± 0.1 RI.sub.α 0.2 ± 0.03 2.0 ± 0.2 S-oligo RII.sub.β 1.5 ± 0.2 0.2 ± 0.02 S-oligo Random S-oligo 1.0 ± 0.1 1.0 ± 0.1 ______________________________________ Treatment with Soligos as indicated were the same as that in FIG. 7B. At the end of the experiment (3 weeks), tumor extracts were prepared as previously described (Ally, S. et al., Cancer Res. 49:5650-5655 (1980)) and immunoblotting and immunoprecipitation of RI.sub.α and RII.sub.β, respectively, were performed as previously described by Ally, S., et al., Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988) and Tortora, G., et al., Proc. Natl. Acad. Sci. USA 87:705-708 (1990). Data are from quantification by densitometric scanning of autoradiograms. Data are expressed relative to levels in control tumors (no treatment), which are set to equal to one as an arbitrary unit. Data represent an average ± S.D. of 7 tumors.
In the following sequence listing, Seq ID No: 1 represents an antisense sequence corresponding to the first 7 N-terminal codons for RI.sub.α. Seq ID No: 2 represents an antisense sequence corresponding to the 8th -13th codon for RI.sub.α. Seq ID No: 3 represents an antisense sequence corresponding to the 14th -20th codon for RI.sub.α. Seq ID No: 4 represents an antisense sequence corresponding to the 94th -100th codon for RI.sub.α. Seq ID No: 5 represents an antisense sequence corresponding to the 1st -100th codon for RI.sub.α. Seq ID No: 6 represents the sense sequence corresponding to the 1st -100th codon for RI.sub.α.
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 7 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: GGCGGTACTGCCAGACTCCAT21 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GCGTGCCTCCTCACTGGC18 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GAGCTCACATTCTCGAAGGCT21 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GATAGCACCTCGTCGCCTCCT21 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: GATAGCACCTCGTCGCCTCCTACCTTTAACCACTGGGTTGGGTGGAGGAGGAGAAATCTC60 ATCCTCCCTTGAGTCTGTACGAGTGCCTGCTTTCTGCAGATTGTGAATCTGTTTTGCCTC120 CTCCTTCTCCAACCTCTCAAAGTATTCCCTGAGGAATGCCATGGGACTCTCAGGTCGAGC180 AGTGCACAACTGCACAATAGAATCTTTGAGCAGTGCTTGAATGTTATGCTTCTGGACGTA240 GAGCTCACATTCTCGAAGGCTGCGTGCCTCCTCACTGGCGGCGGTACTGCCAGACTCCAT300 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: ATGGAGTCTGGCAGTACCGCCGCCAGTGAGGAGGCACGCAGCCTTCGAGAATGTGAGCTC60 TACGTCCAGAAGCATAACATTCAAGCACTGCTCAAAGATTCTATTGTGCAGTTGTGCACT120 GCTCGACCTGAGAGACCCATGGCATTCCTCAGGGAATACTTTGAGAGGTTGGAGAAGGAG180 GAGGCAAAACAGATTCAGAATCTGCAGAAAGCAGGCACTCGTACAGACTCAAGGGAGGAT240 GAGATTTCTCCTCCTCCACCCAACCCAGTGGTTAAAGGTAGGAGGCGACGAGGTGCTATC300 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CGATCGATCGATCGATCGTAC21 __________________________________________________________________________
Claims (6)
1. An oligonucleotide derivative of 15 to 30 nucleotides in length and complementary to a region in the nucleic acid encoding the first 100 N-terminal amino acids of RI.sub.α, which nucleic acid consists of the nucleotide sequence shown as SEQ ID NO: 6.
2. The oligonucleotide derivative of claim 1, wherein said oligonucleotide derivative is a DNA derivative.
3. A pharmaceutical composition comprising at least one oligonucleotide derivative as claimed in claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 wherein said pharmaceutically acceptable carrier is a sterol.
5. The pharmaceutical composition of claim 3 wherein said pharmaceutically acceptable carrier is a liposome.
6. The pharmaceutical composition of claim 3 wherein said oligonucleotide derivative is a DNA derivative.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/383,742 US5691317A (en) | 1990-11-02 | 1995-02-02 | Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60711390A | 1990-11-02 | 1990-11-02 | |
US68019891A | 1991-04-05 | 1991-04-05 | |
US07/702,163 US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US08/060,984 US5627158A (en) | 1990-11-02 | 1993-05-14 | Antisense oligonucleotides of human regulatory subunit RI-.sub.α of camp dependent protein kinases for the treatment of cancer |
US08/383,742 US5691317A (en) | 1990-11-02 | 1995-02-02 | Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/060,984 Continuation US5627158A (en) | 1990-11-02 | 1993-05-14 | Antisense oligonucleotides of human regulatory subunit RI-.sub.α of camp dependent protein kinases for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US5691317A true US5691317A (en) | 1997-11-25 |
Family
ID=27416969
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/702,163 Expired - Lifetime US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US08/060,984 Expired - Fee Related US5627158A (en) | 1990-11-02 | 1993-05-14 | Antisense oligonucleotides of human regulatory subunit RI-.sub.α of camp dependent protein kinases for the treatment of cancer |
US08/383,742 Expired - Fee Related US5691317A (en) | 1990-11-02 | 1995-02-02 | Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/702,163 Expired - Lifetime US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US08/060,984 Expired - Fee Related US5627158A (en) | 1990-11-02 | 1993-05-14 | Antisense oligonucleotides of human regulatory subunit RI-.sub.α of camp dependent protein kinases for the treatment of cancer |
Country Status (9)
Country | Link |
---|---|
US (3) | US5271941A (en) |
EP (3) | EP0972831A1 (en) |
KR (1) | KR0171210B1 (en) |
AT (2) | ATE194383T1 (en) |
CA (2) | CA2054325C (en) |
DE (2) | DE69132299T2 (en) |
DK (2) | DK0785252T3 (en) |
ES (2) | ES2148838T3 (en) |
GR (2) | GR3024673T3 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
WO2005112978A2 (en) | 2004-05-21 | 2005-12-01 | University Of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
US20080050414A1 (en) * | 2004-04-28 | 2008-02-28 | Elford Howard L | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
US20090047250A1 (en) * | 2007-08-13 | 2009-02-19 | Elford Howard L | Methods for treating or preventing neuroinflammation or autoimmune diseases |
EP2116604A1 (en) | 2002-08-05 | 2009-11-11 | University of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
WO2010065617A1 (en) | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
EP2311852A1 (en) | 2002-02-06 | 2011-04-20 | Stasys Technologies, Inc. | Anti-infarction molecules |
US7964577B2 (en) | 2005-10-14 | 2011-06-21 | Donald Carlton D | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US7994130B2 (en) | 2006-12-11 | 2011-08-09 | University Of Utah Research Foundation | Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability |
WO2011103224A1 (en) | 2010-02-19 | 2011-08-25 | Corning Incorporated | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
US20110230442A1 (en) * | 2008-08-15 | 2011-09-22 | Georgetown University | Na channels, disease, and related assays and compositions |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2535355A2 (en) | 2005-03-23 | 2012-12-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP2560001A2 (en) | 2006-09-21 | 2013-02-20 | University of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
US8501912B2 (en) | 2007-12-03 | 2013-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Filipil compositions and methods for treating cancer |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
EP2853897A1 (en) | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
WO2015077566A1 (en) | 2013-11-21 | 2015-05-28 | Huang Zhen | Methods for structural determination of selenium derivatized nucleic acid complexes |
US9422363B2 (en) | 2007-08-28 | 2016-08-23 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
WO2018022967A1 (en) | 2016-07-28 | 2018-02-01 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
WO2018136758A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hsd17b13 variants and uses thereof |
WO2018226560A1 (en) | 2017-06-05 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | B4galt1 variants and uses thereof |
WO2019051033A1 (en) | 2017-09-07 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Solute carrier family 14 member 1 (slc14a1) variants and uses thereof |
WO2019050899A1 (en) | 2017-09-06 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
WO2019075181A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
WO2019079238A1 (en) | 2017-10-16 | 2019-04-25 | Regeneron Pharmaceuticals, Inc. | Cornulin (crnn) variants and uses thereof |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
WO2021003295A1 (en) | 2019-07-02 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
US11123435B2 (en) | 2016-08-03 | 2021-09-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
CA2158347A1 (en) | 1993-03-26 | 1994-10-13 | Renato Baserga | Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
PT1584682E (en) * | 1993-09-20 | 2009-08-03 | Univ Pennsylvania | Regulation of bcl-2 gene expression |
US5618709A (en) * | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
US5726297A (en) * | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US20050054600A1 (en) * | 1995-08-17 | 2005-03-10 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
EP1007656B1 (en) * | 1997-03-12 | 2006-09-13 | Idera Pharmaceuticals, Inc. | Modified protein kinase a-specific hybrid oligonucleotide in combination with paclitaxol and methods of their use |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6312941B1 (en) | 1997-11-26 | 2001-11-06 | The Regents Of The University Of Michigan | Compositions and methods for identifying signaling pathway agonists and antagonists |
AU5618700A (en) * | 1999-06-18 | 2001-01-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
EP2351855A1 (en) | 2000-09-26 | 2011-08-03 | Duke University | RNA aptamers and methods for identifying the same |
KR100408916B1 (en) * | 2000-11-23 | 2003-12-11 | 주식회사 바이오제니아 | An anticancer drug comprising a mycolactone, an antisense Rb oligonucleotide that decreases human retinoblastoma protein expression and an anticancer drug comprising a mycolactone and the said antisense Rb oligonucleotide |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
WO2003093452A2 (en) * | 2002-02-26 | 2003-11-13 | University Of Utah Research Foundation | Variants of nedd4l associated with hypertension and viral budding |
WO2004053073A2 (en) * | 2002-12-05 | 2004-06-24 | The Research Foundation Of State University Of Newyork | HIGH EFFICACY ANTISENSE Riα PKA POLY-DNP OLIGORIBONUCLEOTIDES |
US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
EP2484780A1 (en) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Methods and materials for determining pain sensibility and predicting and treating related disorders |
US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
LT2056845T (en) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | Structure and use of 5` phosphate oligonucleotides |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
ES2893114T3 (en) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Methods for selecting therapeutic molecules |
MX2017010066A (en) | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Tau antisense oligomers and uses thereof. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000624A1 (en) * | 1988-07-05 | 1990-01-25 | Baylor College Of Medecine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
WO1990009180A1 (en) * | 1989-02-15 | 1990-08-23 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5097026A (en) * | 1986-10-28 | 1992-03-17 | Tore Jahnsen | DNA for human regulatory subunits (RIα and RIIβ) of camp-dependent protein kinases |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
-
1991
- 1991-05-20 US US07/702,163 patent/US5271941A/en not_active Expired - Lifetime
- 1991-10-28 CA CA002054325A patent/CA2054325C/en not_active Expired - Fee Related
- 1991-10-28 CA CA002488792A patent/CA2488792A1/en not_active Abandoned
- 1991-10-31 ES ES97100277T patent/ES2148838T3/en not_active Expired - Lifetime
- 1991-10-31 ES ES91118628T patent/ES2104644T3/en not_active Expired - Lifetime
- 1991-10-31 AT AT97100277T patent/ATE194383T1/en not_active IP Right Cessation
- 1991-10-31 EP EP99119780A patent/EP0972831A1/en not_active Withdrawn
- 1991-10-31 EP EP91118628A patent/EP0490077B1/en not_active Expired - Lifetime
- 1991-10-31 AT AT91118628T patent/ATE156517T1/en not_active IP Right Cessation
- 1991-10-31 DK DK97100277T patent/DK0785252T3/en active
- 1991-10-31 DE DE69132299T patent/DE69132299T2/en not_active Expired - Fee Related
- 1991-10-31 DE DE69127175T patent/DE69127175T2/en not_active Expired - Fee Related
- 1991-10-31 DK DK91118628.6T patent/DK0490077T3/en active
- 1991-10-31 EP EP97100277A patent/EP0785252B1/en not_active Expired - Lifetime
- 1991-11-02 KR KR1019910019468A patent/KR0171210B1/en not_active IP Right Cessation
-
1993
- 1993-05-14 US US08/060,984 patent/US5627158A/en not_active Expired - Fee Related
-
1995
- 1995-02-02 US US08/383,742 patent/US5691317A/en not_active Expired - Fee Related
-
1997
- 1997-09-10 GR GR970402319T patent/GR3024673T3/en unknown
-
2000
- 2000-10-02 GR GR20000402225T patent/GR3034535T3/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US5097026A (en) * | 1986-10-28 | 1992-03-17 | Tore Jahnsen | DNA for human regulatory subunits (RIα and RIIβ) of camp-dependent protein kinases |
WO1990000624A1 (en) * | 1988-07-05 | 1990-01-25 | Baylor College Of Medecine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
WO1990009180A1 (en) * | 1989-02-15 | 1990-08-23 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
Non-Patent Citations (134)
Title |
---|
.O slashed.gried, D. et al., "Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination: Principles for optimizing the isozyme specificity of analog combinations," Eur. J. Biochem. 150:219-227 (1985). |
.O slashed.yen, O. et al., "Human Testis cDNA for the regulatory subunit RII.sub.α of cAMP-dependent protein kinase encodes an alternate amino-terminal region," FEBS Letts. 246(1.2):57-64 (1989). |
A. van der Krol et al., BioTechniques, vol. 6 (10) ( 88) pp. 958 976. * |
A. van der Krol et al., BioTechniques, vol. 6 (10) ('88) pp. 958-976. |
Ally, S. et al., "Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth," Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988). |
Ally, S. et al., Selective modulation of protein kinase isozymes by the site selective analog 8 chloroadenosine 3 ,5 cyclic monophosphate provides a biological means for control of human colon cancer cell growth, Proc. Natl. Acad. Sci. USA 85:6319 6322 (1988). * |
Becker, D. et al., "Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor," EMBO J. 8(12):3685-3691 (1989). |
Becker, D. et al., Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor, EMBO J. 8(12):3685 3691 (1989). * |
Beebe, S. J. and Corbin, J. D., "Cyclic Nucleotide-Dependent Protein Kinases," in: The Enzymes, vol. XVII, part A, San Diego: Academic Press, Inc., pp. 43-111 (1986). |
Beebe, S. J. and Corbin, J. D., Cyclic Nucleotide Dependent Protein Kinases, in: The Enzymes , vol. XVII, part A, San Diego: Academic Press, Inc., pp. 43 111 (1986). * |
Campbell, J. M. et al., "Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid," J. Biochem. Biophys. Meth. 20(3):259-267 (Mar. 1990). |
Campbell, J. M. et al., Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, J. Biochem. Biophys. Meth. 20(3):259 267 (Mar. 1990). * |
Cho Chung, Y. S. et al., A RI subunit antisense oligodeoxynucleotide of cAMP dependent protein kinase blocks proliferation in human and rodent cancer cell lines by passing exogenous cAMP effect, Proc. Am. Assoc. Canc. Res. 31:29 Abstract No. 171 (Mar. 1990). * |
Cho Chung, Y. S. et al., Site Selective Cyclic AMP Analogs as New Biological Tools in Growth Control, Differentiation, and Proto oncogene Regulation, Canc. Invest. 7(2):161 177 (1989). * |
Cho-Chung, Y. S. et al., "A RIα subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase blocks proliferation in human and rodent cancer cell lines by-passing exogenous cAMP effect," Proc. Am. Assoc. Canc. Res. 31:29 Abstract No. 171 (Mar. 1990). |
Cho-Chung, Y. S. et al., "Site-Selective Cyclic AMP Analogs as New Biological Tools in Growth Control, Differentiation, and Proto-oncogene Regulation," Canc. Invest. 7(2):161-177 (1989). |
Clair, T. et al., "An antisense oligodeoxynucleotide targeted against the type I regulatory subunit (RIα) mRNA of cAMP-dependent protein kinase (PKA) inhibits the growth of LS-174T human colon carcinoma in athymic mice," Proc. Am. Assoc. Cancer Res. 32:277 Abs. 1645 (Mar. 1991). |
Clair, T. et al., An antisense oligodeoxynucleotide targeted against the type I regulatory subunit (RI ) mRNA of cAMP dependent protein kinase (PKA) inhibits the growth of LS 174T human colon carcinoma in athymic mice, Proc. Am. Assoc. Cancer Res. 32:277 Abs. 1645 (Mar. 1991). * |
Clegg, C. H. et al., "Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase," Proc. Natl. Acad. Sci. USA 85:3703-3707 (1988). |
Clegg, C. H. et al., Genetic characterization of a brain specific form of the type I regulatory subunit of cAMP dependent protein kinase, Proc. Natl. Acad. Sci. USA 85:3703 3707 (1988). * |
Cohen, J. S., "Designing antisense oligonucleotides as pharmaceutical agents," Trends Pharmacol. Sci. 10(11):435-437 (1989). |
Cohen, J. S., "Introduction: Strategies and Realities," in: Topics in Molecular and Structural Biology: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, J. S. Cohen, ed., Boca Raton, Fla.: CRC Press, Inc., pp. 1-6 (1989). |
Cohen, J. S., Designing antisense oligonucleotides as pharmaceutical agents, Trends Pharmacol. Sci. 10(11):435 437 (1989). * |
Cohen, J. S., Introduction: Strategies and Realities, in: Topics in Molecular and Structural Biology: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression , J. S. Cohen, ed., Boca Raton, Fla.: CRC Press, Inc., pp. 1 6 (1989). * |
Corbin, J. D. et al., "The Distribution and Dissociation of Cyclic Adenosine 3':5'-Monophosphate-dependent Protein Kinases in Adipose, Cardiac, and Other Tissues," J. Biol. Chem. 250(1):218-225 (1975). |
Corbin, J. D. et al., The Distribution and Dissociation of Cyclic Adenosine 3 :5 Monophosphate dependent Protein Kinases in Adipose, Cardiac, and Other Tissues, J. Biol. Chem. 250(1):218 225 (1975). * |
DeVita, Jr., V. T., "Principles of Chemotherapy," in: Cancer Principles & Practice of Oncology, V. T. DeVita, Jr. et al., eds., Philadelphia: J.B. Lippincott Co., pp. 257-285 (1985). |
DeVita, Jr., V. T., Principles of Chemotherapy, in: Cancer Principles & Practice of Oncology , V. T. DeVita, Jr. et al., eds., Philadelphia: J.B. Lippincott Co., pp. 257 285 (1985). * |
E. Uhlmann et al., Chemical Reviews, vol. 90 (4) ( 90) pp. 543 584. * |
E. Uhlmann et al., Chemical Reviews, vol. 90 (4) ('90) pp. 543-584. |
Furukawa, Y. et al., "cdc2 Gene Expression at the G1 to S Transition in Human T Lymphocytes," Science 250:805-808 (Nov. 1990). |
Furukawa, Y. et al., cdc2 Gene Expression at the G 1 to S Transition in Human T Lymphocytes, Science 250:805 808 (Nov. 1990). * |
G. Carter et al., Br. J. Cancer 67 ( 93) 869 76 * |
G. Carter et al., Br. J. Cancer 67 ('93) 869-76 |
gried, D. et al., Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination: Principles for optimizing the isozyme specificity of analog combinations, Eur. J. Biochem. 150:219 227 (1985). * |
Guadagni, F. et al., "Carcinoembryonic Antigen Regulation in Human Colorectal Tumor Cells by a Site-Selective Cyclic AMP Analogue: A Comparison with Interferon-gamma," Int. J. Canc. 48(3):413-422 (May 1991). |
Guadagni, F. et al., "Regulation of Carcinoembryonic Antigen Expression in Different Human Colorectal Tumor Cells by Interferon-γ," Canc. Res. 50:6248-6255 (Oct. 1990). |
Guadagni, F. et al., Carcinoembryonic Antigen Regulation in Human Colorectal Tumor Cells by a Site Selective Cyclic AMP Analogue: A Comparison with Interferon gamma, Int. J. Canc. 48(3):413 422 (May 1991). * |
Guadagni, F. et al., Regulation of Carcinoembryonic Antigen Expression in Different Human Colorectal Tumor Cells by Interferon , Canc. Res. 50:6248 6255 (Oct. 1990). * |
Heywood, S. M., "tcRNA as a naturally occurring antisense RNA in eukaryotes," Nucl. Acids Res. 14(16):6771-6772 (1986). |
Heywood, S. M., tcRNA as a naturally occurring antisense RNA in eukaryotes, Nucl. Acids Res. 14(16):6771 6772 (1986). * |
Hofmann, F. et al., "Concentrations of Cyclic AMP-dependent Protein Kinase Subunits in Various Tissues," J. Biol. Chem. 252(4):1441-1447 (1977). |
Hofmann, F. et al., Concentrations of Cyclic AMP dependent Protein Kinase Subunits in Various Tissues, J. Biol. Chem. 252(4):1441 1447 (1977). * |
Iversen, P., "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue," Anti-Canc. Drug Design 6(6):531-538 (Dec. 1991). |
Iversen, P., In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue, Anti Canc. Drug Design 6(6):531 538 (Dec. 1991). * |
Iyer, R. P. et al., "3H-1,2-Benzodithiole-3-one 1,1-Dioxide as an Improved Sulfurizing Reagent in the Solid-Phase Synthesis of Oligodeoxyribonucleoside Phosphorothioates," J. Am. Chem. Soc. 112(3):1253-1254 (Jan. 1990). |
Iyer, R. P. et al., 3H 1,2 Benzodithiole 3 one 1,1 Dioxide as an Improved Sulfurizing Reagent in the Solid Phase Synthesis of Oligodeoxyribonucleoside Phosphorothioates, J. Am. Chem. Soc. 112(3):1253 1254 (Jan. 1990). * |
J. Wermur, Crit. Rev. in Biochem & Mol. Biol., 26 (3/4) ( 91) 227 259. * |
J. Wermur, Crit. Rev. in Biochem & Mol. Biol., 26 (3/4) ('91) 227-259. |
Jahnsen T. et al., "Molecular Cloning, cDNA Structure, and Regulation of the Regulatory Subunit of Type II cAMP-dependent Protein Kinase from Rat Ovarian Granulosa Cells," J. Biol. Chem. 261(26):12352-12361 (1986). |
Jahnsen T. et al., Molecular Cloning, cDNA Structure, and Regulation of the Regulatory Subunit of Type II cAMP dependent Protein Kinase from Rat Ovarian Granulosa Cells, J. Biol. Chem. 261(26):12352 12361 (1986). * |
Jaroszewski, J. W. et al., "Concerning Antisense Inhibition of the Multiple Drug Resistance Gene," Canc. Commun. 2(8):287-294 (Aug. 1990). |
Jaroszewski, J. W. et al., Concerning Antisense Inhibition of the Multiple Drug Resistance Gene, Canc. Commun. 2(8):287 294 (Aug. 1990). * |
Jaskulski, D. et al., "Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin," Science 240:1544-1546 (1988). |
Jaskulski, D. et al., Inhibition of Cellular Proliferation by Antisense Oligodeoxynucleotides to PCNA Cyclin, Science 240:1544 1546 (1988). * |
K. Brigham et al. Am. J. Med. Sci. 298 (4) (Oct. 1989) 278 81. * |
K. Brigham et al. Am. J. Med. Sci. 298 (4) (Oct. 1989) 278-81. |
Katsaros, D. et al., "Site-Selective cyclic AMP analogs provide a new approach in the control of cancer cell growth," FEBS Letts. 223(1):97-103 (1987). |
Katsaros, D. et al., Site Selective cyclic AMP analogs provide a new approach in the control of cancer cell growth, FEBS Letts. 223(1):97 103 (1987). * |
Lee, D. C. et al., "Isolation of a cDNA clone for the type I regulatory subunit of bovine cAMP-dependent protein kinase," Proc. Natl. Acad. Sci. USA 80:3608-3612 (1983). |
Lee, D. C. et al., Isolation of a cDNA clone for the type I regulatory subunit of bovine cAMP dependent protein kinase, Proc. Natl. Acad. Sci. USA 80:3608 3612 (1983). * |
Levy, F. O. et al., "Molecular Cloning, Complimentary Deoxyribonucleic Acid Structure and Predicted Full-Length Amino Acid Sequence of the Hormone-Inducible Regulatory Subunit of 3'-5'-Cyclic Adenosine Monophosphate-Dependent Protein Kinase from Human Testis," Mol. Endo. 2(12):1364-1373 (1988). |
Levy, F. O. et al., Molecular Cloning, Complimentary Deoxyribonucleic Acid Structure and Predicted Full Length Amino Acid Sequence of the Hormone Inducible Regulatory Subunit of 3 5 Cyclic Adenosine Monophosphate Dependent Protein Kinase from Human Testis, Mol. Endo. 2(12):1364 1373 (1988). * |
M. Sandberg et al., Bioch. Biophys. Res. Comm., vol. 149 (3) ( 87) 939 945. * |
M. Sandberg et al., Bioch. Biophys. Res. Comm., vol. 149 (3) ('87) 939-945. |
Milligan, J. F. et al., "Current Concepts in Antisense Drug Design," J. Med. Chem. 36(14):1923-1937 (1993). |
Milligan, J. F. et al., Current Concepts in Antisense Drug Design, J. Med. Chem. 36(14):1923 1937 (1993). * |
Mirabelli, C. K. et al., "In vitro and in vivo pharmacologic activities of antisense oligonucleotides," Anti-Canc. Drug Design 6(6):647-661 (Dec. 1991). |
Mirabelli, C. K. et al., In vitro and in vivo pharmacologic activities of antisense oligonucleotides, Anti Canc. Drug Design 6(6):647 661 (Dec. 1991). * |
Mizuno, T. et al., "A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA)," Proc. Natl. Sci. USA 81:1966-1970 (1984). |
Mizuno, T. et al., A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA), Proc. Natl. Sci. USA 81:1966 1970 (1984). * |
Paterson, B. M. et al., "Structural gene identification and mapping by DNA•mRNA hybrid-arrested cell-free translation," Proc. Natl. Acad. Sci. USA 74(10):4370-4374 (1977). |
Paterson, B. M. et al., Structural gene identification and mapping by DNA mRNA hybrid arrested cell free translation, Proc. Natl. Acad. Sci. USA 74(10):4370 4374 (1977). * |
Perlaky, L. et al., "Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression," Anti-Canc. Drug Design 8:3-14 (1993). |
Perlaky, L. et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression, Anti Canc. Drug Design 8:3 14 (1993). * |
Phillips, R. M. et al., "A Critical Appraisal of the Predictive Value of In Vitro Chemosensitivity Assays," J. Natl. Canc. Inst. 82(18):1457-1468 (Sep. 1990). |
Phillips, R. M. et al., A Critical Appraisal of the Predictive Value of In Vitro Chemosensitivity Assays, J. Natl. Canc. Inst. 82(18):1457 1468 (Sep. 1990). * |
Potera, C., "`Reverse Transformation` Studies Provide Clues for Treating Malignancies," Genet. Eng. News 5(8):20 (1985). |
Potera, C., Reverse Transformation Studies Provide Clues for Treating Malignancies, Genet. Eng. News 5(8):20 (1985). * |
Potts, J. D. et al., "Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β3," Proc. Natl. Acad. Sci. USA 88:1516-1520 (Feb. 1991). |
Potts, J. D. et al., Epithelial mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor 3, Proc. Natl. Acad. Sci. USA 88:1516 1520 (Feb. 1991). * |
Ratajczak, M. Z. et al., "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides," Proc. Natl. Acad. Sci. USA 89:11823-11827 (1992). |
Ratajczak, M. Z. et al., In vivo treatment of human leukemia in a scid mouse model with c myb antisense oligodeoxynucleotides, Proc. Natl. Acad. Sci. USA 89:11823 11827 (1992). * |
Robinson Steiner, A. M. and Corbin, J. D., Probable Involvement of Both Intrachain cAMP Binding Sites in Activation of Protein Kinase, J. Biol. Chem. 258(2):1032 1040 (1983). * |
Robinson-Steiner, A. M. and Corbin, J. D., "Probable Involvement of Both Intrachain cAMP Binding Sites in Activation of Protein Kinase," J. Biol. Chem. 258(2):1032-1040 (1983). |
S. Crooke, Annu. Rev. Pharmacol. Toxicol., vol. 32 ( 92), 329 76. * |
S. Crooke, Annu. Rev. Pharmacol. Toxicol., vol. 32 ('92), 329-76. |
Schwartz, D. A. and Rubin, C. S., "Identification and Differential Expression of Two Forms of Regulatory Subunits (RII) of cAMP-dependent Protein Kinase II in Friend Erythroleukemic Cells: Differentiation and 8-bromo-cAMP Elicit a Large and Selective Increase in the Rate of Biosynthesis of Only One Typre of RII," J. Biol. Chem. 260(10):6296-6303 (1985). |
Schwartz, D. A. and Rubin, C. S., Identification and Differential Expression of Two Forms of Regulatory Subunits (RII) of cAMP dependent Protein Kinase II in Friend Erythroleukemic Cells: Differentiation and 8 bromo cAMP Elicit a Large and Selective Increase in the Rate of Biosynthesis of Only One Typre of RII, J. Biol. Chem. 260(10):6296 6303 (1985). * |
Scott, J. D. et al., "The molecular cloning of a type II regulatory subunit of the cAMP-dependent protein kinase from rat skeletal muscle and mouse brain," Proc. Natl. Acad. Sci. USA 84:5192-5196 (1987). |
Scott, J. D. et al., The molecular cloning of a type II regulatory subunit of the cAMP dependent protein kinase from rat skeletal muscle and mouse brain, Proc. Natl. Acad. Sci. USA 84:5192 5196 (1987). * |
Smith, K. A. et al., "Differences in Chemosensitivity Between Subcutaneous and Pulmonary Tumours," Eur. J. Canc. Clin. Oncol. 21(2):249-256 (1985). |
Smith, K. A. et al., Differences in Chemosensitivity Between Subcutaneous and Pulmonary Tumours, Eur. J. Canc. Clin. Oncol. 21(2):249 256 (1985). * |
Stein, C. A. and and Cheng, Y. C., "Antisense Oligonucleotides as Therapeutic Agents--Is the Bullet Really Magical?," Science 261:1004-1012 (1993). |
Stein, C. A. and and Cheng, Y. C., Antisense Oligonucleotides as Therapeutic Agents Is the Bullet Really Magical , Science 261:1004 1012 (1993). * |
Stein, C. A. and Cohen, J. S., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review," Canc. Res. 48:2659-2668 (1988). |
Stein, C. A. and Cohen, J. S., "Phosphorothioate Oligodeoxynucleotide Analogues," in: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, Cohen, ed., Boca Raton, Fla.: CRC Press, Inc., pp. 97-117 (1989). |
Stein, C. A. and Cohen, J. S., Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review, Canc. Res. 48:2659 2668 (1988). * |
Stein, C. A. and Cohen, J. S., Phosphorothioate Oligodeoxynucleotide Analogues, in: Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression , Cohen, ed., Boca Raton, Fla.: CRC Press, Inc., pp. 97 117 (1989). * |
Stokes, C. L., "The pros and cons of drug `trafficking`," Nature Med. 1(11):1135-1136 (1995). |
Stokes, C. L., The pros and cons of drug trafficking , Nature Med. 1(11):1135 1136 (1995). * |
Storey, A. et al., "Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16," Nuc. Acids Res. 19(15):4109-4114 (Aug. 1991). |
Storey, A. et al., Anti sense phosphorothioate oligonucleotides have both specific and non specific effects on cells containing human papillomavirus type 16, Nuc. Acids Res. 19(15):4109 4114 (Aug. 1991). * |
Sugden, P. H. and Corbin, J. D., "Adenosine 3':5'-Cyclic Monophosphate-Binding Proteins in Bovine and Rat Tissues," Biochem. J. 159:423-437 (1976). |
Sugden, P. H. and Corbin, J. D., Adenosine 3 :5 Cyclic Monophosphate Binding Proteins in Bovine and Rat Tissues, Biochem. J. 159:423 437 (1976). * |
Szczylik, C. et al., "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides," Science 253:562-565 (Aug. 1991). |
Szczylik, C. et al., Selective Inhibition of Leukemia Cell Proliferation by BCR ABL Antisense Oligodeoxynucleotides, Science 253:562 565 (Aug. 1991). * |
Tagliaferri, P. et al., "Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-selective Cyclic AMP Analogs," J. Biol. Chem. 263(1):409-416 (1988). |
Tagliaferri, P. et al., Reverse Transformation of Harvey Murine Sarcoma Virus transformed NIH/3T3 Cells by Site selective Cyclic AMP Analogs, J. Biol. Chem. 263(1):409 416 (1988). * |
Taylor, S. S. et al., "cAMP-dependent protein kinase: prototype for a family of enzymes," FASEB J. 2:2677-2685 (1988). |
Taylor, S. S. et al., cAMP dependent protein kinase: prototype for a family of enzymes, FASEB J. 2:2677 2685 (1988). * |
Tortora, G. and Cho Chung, Y. S., Type II Regulatory Subunit of Protein Kinase Restores cAMP dependent Transcription in a cAMP unresponsive Cell Line, J. Biol. Chem. 265(30):18067 18070 (Oct. 1990). * |
Tortora, G. and Cho-Chung, Y. S., "Type II Regulatory Subunit of Protein Kinase Restores cAMP-dependent Transcription in a cAMP-unresponsive Cell Line," J. Biol. Chem. 265(30):18067-18070 (Oct. 1990). |
Tortora, G. et al., "A RIα subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase inhibits proliferation of human HL-60 promyelocytic leukemia," Proc. Am. Assoc. Canc. Res. 31:38 Abstract No. 220 (Mar. 1990). |
Tortora, G. et al., "An antisense oligodeoxynucleotide targeted against the type IIβ regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects," Proc. Natl. Acad. Sci. USA 87:705-708 (Jan. 1990). |
Tortora, G. et al., "Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase," Proc. Natl. Acad. Sci. USA 88:2011-2015 (Mar. 1991). |
Tortora, G. et al., "Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells," Proc. Natl. Acad. Sci. USA 86:2849-2852 (1989). |
Tortora, G. et al., "Site-Selective cAMP Analogs at Micromolar Concentrations Induce Growth Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and Acute Lymphocytic Human Leukemia Cell Lines," Blood 71(1):230-233 (1988). |
Tortora, G. et al., A RI subunit antisense oligodeoxynucleotide of cAMP dependent protein kinase inhibits proliferation of human HL 60 promyelocytic leukemia, Proc. Am. Assoc. Canc. Res. 31:38 Abstract No. 220 (Mar. 1990). * |
Tortora, G. et al., An antisense oligodeoxynucleotide targeted against the type II regulatory subunit mRNA of protein kinase inhibits cAMP induced differentiation in HL 60 leukemia cells without affecting phorbol ester effects, Proc. Natl. Acad. Sci. USA 87:705 708 (Jan. 1990). * |
Tortora, G. et al., Differentiation of HL 60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP dependent protein kinase, Proc. Natl. Acad. Sci. USA 88:2011 2015 (Mar. 1991). * |
Tortora, G. et al., Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site selective cAMP analogs in K 562 human leukemic cells, Proc. Natl. Acad. Sci. USA 86:2849 2852 (1989). * |
Tortora, G. et al., Site Selective cAMP Analogs at Micromolar Concentrations Induce Growth Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and Acute Lymphocytic Human Leukemia Cell Lines, Blood 71(1):230 233 (1988). * |
Tseng, B. Y. and Brown, K. D., "Antisense oligonucleotide technology in the development of cancer therapeutics," Canc. Gene Therapy 1(1):65-71 (1994). |
Tseng, B. Y. and Brown, K. D., Antisense oligonucleotide technology in the development of cancer therapeutics, Canc. Gene Therapy 1(1):65 71 (1994). * |
Weiss, R., "Upping the Antisense Ante: Scientists bet on profits from reverse genetics," Science 139:108-109 (Feb. 1991). |
Weiss, R., Upping the Antisense Ante: Scientists bet on profits from reverse genetics, Science 139:108 109 (Feb. 1991). * |
Westermann, P. et al., "Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides," Biomed. Biochim. Acta 48(1):85-93 (1989). |
Westermann, P. et al., Inhibition of expression of SV40 virus large T antigen by antisense oligodeoxyribonucleotides, Biomed. Biochim. Acta 48(1):85 93 (1989). * |
Y. Cho Chung, J. NCI, vol. 81 (13) ( 89) pp. 982 987. * |
Y. Cho-Chung, J. NCI, vol. 81 (13) ('89) pp. 982-987. |
yen, O. et al., Human Testis cDNA for the regulatory subunit RII of cAMP dependent protein kinase encodes an alternate amino terminal region, FEBS Letts. 246(1.2):57 64 (1989). * |
Zirvi,. K. A. et al., "Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice," Canc. Lett. 72:39-44 (1993). |
Zirvi,. K. A. et al., Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice, Canc. Lett. 72:39 44 (1993). * |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
EP2363405A1 (en) | 2002-02-06 | 2011-09-07 | Stasys Technologies, Inc. | Anti-infarction molecules |
EP2311852A1 (en) | 2002-02-06 | 2011-04-20 | Stasys Technologies, Inc. | Anti-infarction molecules |
EP2116604A1 (en) | 2002-08-05 | 2009-11-11 | University of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
US20080050414A1 (en) * | 2004-04-28 | 2008-02-28 | Elford Howard L | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders |
US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
WO2005112978A2 (en) | 2004-05-21 | 2005-12-01 | University Of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
EP3312196A1 (en) | 2005-03-23 | 2018-04-25 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
EP2567976A2 (en) | 2005-03-23 | 2013-03-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP2551282A2 (en) | 2005-03-23 | 2013-01-30 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP2535355A2 (en) | 2005-03-23 | 2012-12-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
EP3153525A1 (en) | 2005-03-23 | 2017-04-12 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
US8431546B2 (en) | 2005-10-14 | 2013-04-30 | Phigenix, Inc. | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2392646A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
EP2392645A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
EP2392647A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
EP2395076A1 (en) | 2005-10-14 | 2011-12-14 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US11033628B1 (en) | 2005-10-14 | 2021-06-15 | Phigenix, Inc. | Targeting PAX2 for the treatment of breast cancer |
US7964577B2 (en) | 2005-10-14 | 2011-06-21 | Donald Carlton D | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
EP2402435A2 (en) | 2005-10-14 | 2012-01-04 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8735365B2 (en) | 2005-10-14 | 2014-05-27 | Phigenix, Inc. | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8318692B2 (en) | 2005-10-14 | 2012-11-27 | Donald Carlton D | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8653021B2 (en) | 2005-10-14 | 2014-02-18 | Phigenix, Inc. | Targeting PAX2 for the treatment of breast cancer |
US8633149B2 (en) | 2005-10-14 | 2014-01-21 | Phigenix, Inc. | Targeting PAX2 for the treatment of breast cancer |
US8461101B2 (en) | 2005-10-14 | 2013-06-11 | Phigenix, Inc. | Targeting PAX2 for the treatment of breast cancer |
US8394780B2 (en) | 2005-10-14 | 2013-03-12 | Phigenix, Inc. | Targeting PAX2 for the treatment of breast cancer |
EP2560001A2 (en) | 2006-09-21 | 2013-02-20 | University of Rochester | Compositions and methods related to protein displacement therapy for myotonic distrophy |
EP3034083A2 (en) | 2006-09-21 | 2016-06-22 | University of Rochester | Antisense oligonucleotides for use in treating myotonic dystrophy |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
US7994130B2 (en) | 2006-12-11 | 2011-08-09 | University Of Utah Research Foundation | Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability |
US8309519B2 (en) | 2006-12-11 | 2012-11-13 | University Of Utah Research Foundation | Compositions and methods for inhibiting vascular permeability |
US20090047250A1 (en) * | 2007-08-13 | 2009-02-19 | Elford Howard L | Methods for treating or preventing neuroinflammation or autoimmune diseases |
US9526707B2 (en) | 2007-08-13 | 2016-12-27 | Howard L. Elford | Methods for treating or preventing neuroinflammation or autoimmune diseases |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US9422363B2 (en) | 2007-08-28 | 2016-08-23 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US9279009B2 (en) | 2007-12-03 | 2016-03-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | FILIP1L nucleic acid fragments |
US8501912B2 (en) | 2007-12-03 | 2013-08-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Filipil compositions and methods for treating cancer |
EP2853897A1 (en) | 2008-05-08 | 2015-04-01 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
US8816095B2 (en) | 2008-08-15 | 2014-08-26 | Georgetown University | Na channels, disease, and related assays and compositions |
US20110230442A1 (en) * | 2008-08-15 | 2011-09-22 | Georgetown University | Na channels, disease, and related assays and compositions |
WO2010065617A1 (en) | 2008-12-02 | 2010-06-10 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
WO2011103224A1 (en) | 2010-02-19 | 2011-08-25 | Corning Incorporated | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
EP3613774A1 (en) | 2010-06-09 | 2020-02-26 | Genmab A/S | Antibodies against human cd38 |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
US9970002B2 (en) | 2012-12-12 | 2018-05-15 | Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
WO2015077566A1 (en) | 2013-11-21 | 2015-05-28 | Huang Zhen | Methods for structural determination of selenium derivatized nucleic acid complexes |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
WO2018022967A1 (en) | 2016-07-28 | 2018-02-01 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
EP4230648A2 (en) | 2016-07-28 | 2023-08-23 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
US11123435B2 (en) | 2016-08-03 | 2021-09-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
WO2018136758A1 (en) | 2017-01-23 | 2018-07-26 | Regeneron Pharmaceuticals, Inc. | Hsd17b13 variants and uses thereof |
WO2018226560A1 (en) | 2017-06-05 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | B4galt1 variants and uses thereof |
WO2019050899A1 (en) | 2017-09-06 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
WO2019051033A1 (en) | 2017-09-07 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | Solute carrier family 14 member 1 (slc14a1) variants and uses thereof |
WO2019075181A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
EP4234719A2 (en) | 2017-10-11 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
WO2019079238A1 (en) | 2017-10-16 | 2019-04-25 | Regeneron Pharmaceuticals, Inc. | Cornulin (crnn) variants and uses thereof |
WO2021003295A1 (en) | 2019-07-02 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0490077A1 (en) | 1992-06-17 |
EP0972831A1 (en) | 2000-01-19 |
DK0490077T3 (en) | 1998-01-26 |
KR0171210B1 (en) | 1999-02-01 |
EP0785252B1 (en) | 2000-07-05 |
DE69132299D1 (en) | 2000-08-10 |
ATE156517T1 (en) | 1997-08-15 |
CA2054325C (en) | 2005-03-15 |
DE69127175T2 (en) | 1998-03-12 |
ES2104644T3 (en) | 1997-10-16 |
DE69127175D1 (en) | 1997-09-11 |
CA2054325A1 (en) | 1992-05-03 |
US5627158A (en) | 1997-05-06 |
EP0785252A1 (en) | 1997-07-23 |
GR3034535T3 (en) | 2001-01-31 |
CA2488792A1 (en) | 1992-05-03 |
GR3024673T3 (en) | 1997-12-31 |
DE69132299T2 (en) | 2001-02-15 |
ATE194383T1 (en) | 2000-07-15 |
EP0490077B1 (en) | 1997-08-06 |
DK0785252T3 (en) | 2000-10-02 |
US5271941A (en) | 1993-12-21 |
ES2148838T3 (en) | 2000-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5691317A (en) | Antisense oligonucleotides of human regulatory subunit RI-alpha of cAMP dependent protein kinases for the treatment of cancer | |
US5248671A (en) | Methods and compositions for treatment of cancer using oligonucleotides | |
Tortora et al. | Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. | |
US5087617A (en) | Methods and compositions for treatment of cancer using oligonucleotides | |
Kamesaki et al. | bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair | |
US20030012812A1 (en) | Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides | |
Tari et al. | Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia | |
WO1999007844A2 (en) | Methods and compositions for treatment of restenosis | |
US20030215489A1 (en) | Chemosensitizing with liposomes containing oligonucleotides | |
Wang et al. | Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms | |
Wu et al. | Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells | |
CA2232724A1 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
KR100913860B1 (en) | Oligonucleotide compositions and their use to induce differentiation of cells | |
KR100971571B1 (en) | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides | |
JP3150609B2 (en) | Antisense oligonucleotides for cancer treatment | |
WO1998007415A2 (en) | Methods for prevention of cellular proliferation and restenosis | |
Baguley et al. | A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine | |
JP2004528851A (en) | Epidermal growth factor receptor antisense oligonucleotides | |
JP2004505890A (en) | Methods for treating cells resistant to antineoplastic agents | |
CHO-CHUNG | Protein kinase A-directed antisense restrains cancer growth: sequence-specific inhibition of gene expression | |
JP2004528851A6 (en) | Antisense oligonucleotide for epidermal growth factor receptor | |
US6774143B1 (en) | Method for treating cells resistant to antineoplastic agents | |
JPH06501024A (en) | Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors | |
US20050054600A1 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
Bennett et al. | Antisense Oligonucleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20091125 |